Opiant Pharmaceuticals (OPNT) 10-K 21 Mar 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 15, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Registrant Name	OPIANT PHARMACEUTICALS, INC.
Entity Central Index Key	0001385508
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 39,182,880
Trading Symbol	OPNT
Entity Common Stock, Shares Outstanding		3,925,361

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017
Current assets
Cash and cash equivalents	$ 24,613,638	$ 8,115,903	$ 6,872,555
Accounts receivable	4,489,317	11,696,676	3,750,000
Prepaid expenses and other current assets	267,623	733,328	164,887
Deferred financing costs	0	209,042	0
Total current assets	29,370,578	20,754,949	10,787,442
Other assets
Computer equipment, net	0	1,183	2,753
Patents and patent applications, net	15,746	17,118	17,690
Total assets	29,386,324	20,773,250	10,807,885
Current liabilities
Accounts payable and accrued liabilities	1,132,960	3,156,992	2,211,971
License fees payable	5,400,000	0	0
Accrued salaries and wages	1,083,644	713,489	1,701,359
Royalty payable	998,305	1,408,012	0
Deferred revenue	1,212,149	378,700	253,619
Total current liabilities	9,827,058	5,657,193	4,166,949
Long-term liabilities
Deferred revenue	0	2,115,805	2,306,527
License fees payable, net of current portion	2,700,000	0	0
Total liabilities	12,527,058	7,772,998	6,473,476
Stockholders' equity
Common stock; par value $0.001; 200,000,000 shares authorized; 3,845,361, 2,535,766 and 2,026,608 shares issued and outstanding at December 31, 2018, 2017, and July 31, 2017, respectively.	3,846	2,536	2,026
Additional paid-in capital	91,276,086	66,223,066	58,937,112
Accumulated deficit	(74,420,666)	(53,225,350)	(54,604,729)
Total stockholders' equity	16,859,266	13,000,252	4,334,409
Total liabilities and stockholders' equity	$ 29,386,324	$ 20,773,250	$ 10,807,885

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017
Stockholders' equity
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock authorized (in shares)	200,000,000	200,000,000	200,000,000
Common stock issued (in shares)	3,845,361	2,535,766	2,026,608
Common stock outstanding (in shares)	3,845,361	2,535,766	2,026,608

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Revenues
Royalty and licensing revenue	$ 11,696,676	$ 13,262,321	$ 18,406,142
Treatment investment revenue	65,641	250,549	39,854
Grant and contract revenue	0	469,307	0
Total Revenue	11,762,317	13,982,177	18,445,996
Operating expenses
General and administrative	5,887,135	11,263,804	6,530,533
Research and development	2,486,514	8,478,817	3,171,599
Royalty expenses	1,408,012	1,491,099	0
License fees	0	13,725,000	0
Selling expenses	438,625	213,897	1,651,099
Total operating expenses	10,220,286	35,172,617	11,353,231
Income (loss) from operations	1,542,031	(21,190,440)	7,092,765
Other income (expense)
Interest income, net	10,401	144,696	19,966
Gain (loss) on foreign exchange	10,027	(48,306)	18,356
Loss on settlement of liability	(13,917)	(49,983)	0
Total other income	6,511	46,407	38,322
Income (loss) before provision for income taxes	1,548,542	(21,144,033)	7,131,087
Provision for income taxes	169,163	51,283	550,474
Net income (loss)	$ 1,379,379	$ (21,195,316)	$ 6,580,613
Income (loss) per share of common stock:
Basic (in shares)	$ 0.66	$ (7.10)	$ 3.27
Diluted (in shares)	$ 0.31	$ (7.10)	$ 2.94
Weighted average common stock outstanding
Basic (in dollars per share)	2,077,663	2,985,335	2,014,540
Diluted (in dollars per share)	4,393,138	2,985,335	2,235,851

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning Balance (in shares) at Jul. 31, 2016		1,992,433
Beginning Balance at Jul. 31, 2016	$ (4,704,956)	$ 1,992	$ 56,478,394	$ (61,185,342)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reconciling adjustment to record shares issued in prior year for the conversion of debt into common stock in relation to 1:100 reverse stock split (in shares)		6,228
Reconciling adjustment to record shares issued in prior year for the conversion of debt into common stock in relation to 1:100 reverse stock split	0	$ 6	(6)
Stock issued for services (in shares)		27,947
Stock issued for services	190,427	$ 28	190,399
Stock based compensation from issuance of options	1,277,139		1,277,139
Stock based compensation from issuance of warrants	229,360		229,360
Forgiveness of related party debt	761,826		761,826
Net income (loss)	6,580,613			6,580,613
Ending Balance (in shares) at Jul. 31, 2017		2,026,608
Ending Balance at Jul. 31, 2017	4,334,409	$ 2,026	58,937,112	(54,604,729)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation from issuance of options	1,779,671		1,779,671
Exercise of stock options (in shares)		145,630
Exercise of stock options	0	$ 146	(146)
Exercise of warrants (in shares)		356,790
Exercise of warrants	5,292,876	$ 357	5,292,519
Stock issued as settlement of liability (in shares)		6,738
Stock issued as settlement of liability	213,917	$ 7	213,910
Net income (loss)	1,379,379			1,379,379
Ending Balance (in shares) at Dec. 31, 2017		2,535,766
Ending Balance at Dec. 31, 2017	13,000,252	$ 2,536	66,223,066	(53,225,350)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued for services (in shares)		44,664
Stock issued for services	882,232	$ 45	882,187
Stock Issued During Period, Shares, Issued to Net Profit Partners		160,000
Stock Issued During Period, Value, Issued to Net Profit Partners	1,600,000	$ 160	1,599,840
Stock based compensation from issuance of options	5,760,432		5,760,432
Exercise of stock options (in shares)		50,497
Exercise of stock options	0	$ 50	(50)
Exercise of warrants (in shares)		3,400
Exercise of warrants	34,000	$ 3	33,997
Issuance of common stock for cash, net of issuance costs (in shares)		1,051,034
Issuance of common stock for cash, net of issuance costs	16,777,666	$ 1,052	16,776,614
Net income (loss)	(21,195,316)			(21,195,316)
Ending Balance (in shares) at Dec. 31, 2018		3,845,361
Ending Balance at Dec. 31, 2018	$ 16,859,266	$ 3,846	$ 91,276,086	$ (74,420,666)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Stock split conversion ratio	0.01

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Cash flows provided by (used in) operating activities
Net loss	$ 1,379,379	$ (21,195,316)	$ 6,580,613
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	2,142	2,556	5,140
Issuance of common stock for services	0	732,249	190,427
Stock based compensation from issuance of options	1,779,671	5,760,432	1,277,139
Loss on settlement of liability	13,917	49,983	0
Stock based compensation from issuance of warrants	0	0	229,360
Changes in assets and liabilities:
Accounts receivable	(7,946,676)	7,207,359	(3,437,502)
Prepaid expenses and other current assets	(568,441)	465,705	(102,483)
Accounts payable and accrued expenses	1,145,021	(1,924,032)	2,071,387
License fees payable	0	8,100,000	0
Accrued salaries and wages	(987,870)	370,155	(1,218,065)
Royalty payable	1,408,012	(409,707)	0
Deferred revenue	(65,641)	317,644	(39,854)
Net cash provided by (used in) operating activities	(3,840,486)	(522,972)	5,556,162
Cash flows provided by (used in) financing activities
Proceeds from warrant exercise	5,292,876	34,000	0
Deferred financing costs	(209,042)	(166,419)	0
Proceeds from sale of common stock	0	17,153,126	0
Repayment of note payable	0	0	(165,000)
Net cash provided by (used in) financing activities	5,083,834	17,020,707	(165,000)
Net increase in cash and cash equivalents	1,243,348	16,497,735	5,391,162
Cash and cash equivalents, beginning of period	6,872,555	8,115,903	1,481,393
Cash and cash equivalents, end of period	8,115,903	24,613,638	6,872,555
Supplemental disclosure
Interest paid during the period	0	0	4,828
Taxes paid during the period	619,225	174,000	0
Non-Cash Financing Transactions
Cashless exercise of options	146	50	0
Issuance of common stock to net profit partner	0	1,600,000	0
Issuance of common stock as settlement of liability	200,000	100,000	0
Forgiveness of related party of debt	0	0	761,826
Reconciling adjustment to record shares issued in prior year for the conversion of debt into common stock and rounding in relation to 1-for-100 reverse stock split	0	0	6
Offset of deferred financing costs against APIC	$ 0	$ 209,042	$ 0

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals)	12 Months Ended
	Dec. 31, 2017
Statement of Cash Flows [Abstract]
Stock split conversion ratio	0.01

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Opiant Pharmaceuticals, Inc. (the “Company”), a Nevada corporation, is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company was incorporated in the State of Nevada on June 21, 2005 as Madrona Ventures, Inc. and, on September 16, 2009, the Company changed its name to Lightlake Therapeutics Inc. On January 28, 2016, the Company again changed its name to Opiant Pharmaceuticals, Inc. The Company also has developed a treatment to reverse opioid overdoses, which is now known as NARCAN®. On October 2, 2017, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to an Agreement and Plan of Merger, dated October 2, 2017, whereby the Company merged with and into its recently formed, wholly-owned Delaware subsidiary, Opiant Pharmaceuticals, Inc. Pursuant to the Agreement and Plan of Merger, (i) the Company merged with and into its Delaware subsidiary, (ii) the Company's separate corporate existence in Nevada ceased to exist,(iii) the Company's Delaware subsidiary became the surviving corporation, (iv) each share of the Company's common stock, $0.001 par value per share ("Common Stock"), outstanding immediately prior to the effective time was converted into one fully-paid and non-assessable share of Common Stock of Opiant Pharmaceuticals, Inc., a Delaware corporation, and (v) the certificate of incorporation and bylaws of the Company's Delaware subsidiary were adopted as the Company's certificate of incorporation and bylaws at the effective time of the merger. The merger and the Agreement and Plan of Merger were approved by the Company's Board of Directors (the "Board") and stockholders representing a majority of the Company's outstanding Common Stock. On December 8, 2017, the Board of Directors, acting pursuant to Section 5.1 of the Company’s Bylaws, approved a resolution changing the Company’s fiscal year-end from July 31 to December 31. The Company made this change to align its fiscal year end with other companies within its industry.

Liquidity and Financial Conditi

Liquidity and Financial Condition	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Financial Condition	Liquidity and Financial Condition The Company had a net loss of $21.2 million for the year ended December 31, 2018 and has an accumulated deficit of $74.4 million at December 31, 2018. The Company has $19.5 million of working capital at December 31, 2018. The Company has financed its operations from sale of common stock, and through non-equity cash investments by a number of investors, in exchange for an interest in any pre-tax profits received by the Company that was derived from the sale of the Opioid Overdose Reversal Treatment Product less any and all expenses incurred by and payments made by the Company in connection with the Opioid Overdose Reversal Treatment Product ("OORT") (see Note 8 – Deferred Revenue). On September 27, 2018, the Company completed a registered public offering with Cantor Fitzgerald as underwriter and sold 811,764 shares of its Common stock (including 105,882 shares purchased by Cantor Fitzgerald upon the exercise in full of its right to purchase up to an additional 105,882 shares to cover over-allotments) at a price of $17.00 per share. The Company received approximately $13.0 million of net proceeds from the offering after deducting sales commissions. In addition, during the year ended December 31, 2018, the Company sold 239,270 shares of Common Stock under the Sales Agreement entered into with Cantor Fitzgerald for gross proceeds of $4.31 million and received net proceeds of $4.18 million , after sales commissions. The Company believes that it has sufficient capital resources to sustain operations through at least the next twelve months from the date of this filing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Principles of Consolidation The consolidated financial statements have been prepared in accordance with GAAP and include the accounts for the Company and its wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited. All inter-company transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents were $24.6 million , $8.1 million and $6.9 million at December 31, 2018, December 31, 2017 and July 31, 2017, respectively. The Company maintains cash balances at financial institutions insured up to $250,000 by the Federal Deposit Insurance Corporation ("FDIC") and as of December 31, 2018 maintains the majority of its cash balances in money market funds not insured by the FDIC. The Company also transfers certain daily available cash balances to an overnight account which earns interest and the amounts are not insured by the FDIC. Balances in the United Kingdom are insured up to £85,000 by the Financial Services Compensation Scheme (United Kingdom Equivalent). Although the Company’s cash balances exceeded these insured amounts, the Company has not experienced any losses on its cash and cash equivalents for the periods presented. Accounts Receivable The Company routinely assesses the recoverability of receivables to determine their collectability by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay. The Company determines its allowance for doubtful accounts by considering such factors as the length of time balances are past due, the Company’s previous loss history, the customer’s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company has evaluated its accounts receivable history and determined that no allowance for doubtful accounts is required for the year ended December 31, 2018 and the periods ended December 31, 2017 and July 31, 2017. At December 31, 2018 and 2017 the Company's accounts receivable were primarily concentrated with one party, Adapt. At July 31, 2017, 100% of the Company's accounts receivable was concentrated with one party, SWK (see Note 5 - Accounts Receivable). Long-Lived Assets The Company follows ASC 360, Property, Plant, and Equipment , for its fixed assets. Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed by the straight-line method over estimated useful lives ( 3 to 7 years ). The Company’s capitalizes all asset purchases greater than $2,500 having a useful life greater than one year. The Company follows ASC 350, Intangibles – Goodwill and Other for its intellectual property asset. Intellectual property consists of patents which are stated at their fair value acquisition cost. Amortization is calculated by the straight-line method over their estimated useful lives ( 20 years ). The Company recorded depreciation and amortization of $2,556 for the year ended December 31, 2018, $2,142 for the five months ended December 31, 2017 and $5,140 and for the year ended July 31, 2017. Long-lived assets such as property and equipment and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. The Company did no t recognize any impairment losses for any years presented. Earnings (Loss) per Share The Company follows ASC 260, Earnings per Share . Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the respective period presented in the Company’s accompanying consolidated financial statements. Fully diluted earnings (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of Common Stock equivalents (primarily outstanding options and warrants). Common Stock equivalents represent the dilutive effect of the assumed exercise of outstanding stock options and warrants, using the treasury stock method, at either the beginning of the respective period presented or the date of issuance, whichever is later, and only if the Common Stock equivalents are considered dilutive based upon the Company’s net income position at the calculation date. At December 31, 2018, dilutive common stock equivalents have not been included because it would be anti-dilutive. At December 31, 2018, potentially dilutive common stock equivalents are 3,582,560 which consist of options and warrants. The following table illustrates the dilutive effect of the assumed exercise of the Company’s outstanding stock options and warrants, using the treasury stock method, as of December 31, 2017 and July 31, 2017, respectively: Year Ended Five Months ended Year Ended Numerator: December 31, 2018 December 31, 2017 July 31, 2017 Net Income (loss) $ (21,195,316 ) $ 1,379,379 $ 6,580,613 Denominator: Denominator for basic income (loss) per share - weighted average shares 2,985,335 2,077,663 2,014,540 Effect of dilutive securities: Equity incentive plans — 2,315,475 221,311 Denominator for diluted income (loss) per share 2,985,335 4,393,138 2,235,851 Income (loss) per share - Basic $ (7.10 ) $ 0.66 $ 3.27 Income (loss) per share - Diluted $ (7.10 ) $ 0.31 $ 2.94 Research and Development Costs The Company follows ASC 730, Research and Development , and expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation Foreign Currency Translation The Company’s functional and reporting currency is the United States dollar. Transactions occur in British Pounds and management has adopted ASC 830, Foreign Currency Translation Matters . Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. Stock-Based Compensation ASC 718 Compensation – Stock Compensation prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity – Based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. The Company had stock-based compensation of $5.7 million , $1.8 million , and $1.7 million for the year ended December 31, 2018, the five months ended December 31, 2017 and for the year ended July 31, 2017, respectively. Fair Value of Financial Instruments ASC 820 Fair Value Measurements and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1)market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The fair value of the Company’s note payable is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value. As of December 31, 2018, December 31, 2017 and July 31, 2017, the Company did no t have any financial liabilities measured and recorded at fair value on the Company’s balance sheets on a recurring basis. Related Parties The Company follows ASC 850, Related Party Disclosures , for the identification of related parties and disclosure of related party transactions. Related party balances as of December 31, 2018, December 31, 2017 and July 31, 2017 were zero . The Company uses office space free of charge from related parties (see Note 4 - Related Party Transactions). Revenue Recognition The Company generates a large majority of revenue from the agreement with Adapt. During the year ended December 31, 2018 and the five months ended December 31, 2017 the Company recognized 95% and 99% , respectively of revenue from its agreement with Adapt. In May 2014, the FASB issued an accounting standard update (‘ASU”), 2014-09, Revenue from Contracts with Customers (Topic 606). This ASU amends the existing accounting standards for revenue recognition and is based on the principle that revenue should be recognized to depict the transfer of goods or services to a customer at an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On January 1, 2018, the Company adopted the new Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers using the modified retrospective method, and the Company determined the new guidance does not change the Company's policy of revenue recognition. The Company's primary source of revenue is through the recognition of royalty and milestone payments from Adapt. Milestone revenue is recognized upon successful accomplishment of certain sales targets set forth in the Adapt Agreement. Royalty revenue is determined based on the agreed upon royalty rate applied to NARCAN sales reported by Adapt.There are no performance obligations by the Company and the Company recognizes revenue according to the royalty report provided by Adapt on quarterly basis. In regards to treatment revenue, the Company received certain investments from investors in return for an interest in its existing treatments. Investors carry an option to exchange investment into shares of the Company. Revenue is deferred until such time that the option expires or milestones are achieved that eliminate the investor’s right to exercise the option. Once the option has expired, the Company determined its performance obligations under the agreement which typically is to perform R&D services related to treatments and recognizes revenue over a period of time which is usually the expected research and development period. The treatment revenue is disaggregated by program treatments. (See Note 8 to the Consolidated Financial Statements - Deferred Revenue). In June 2018, the FASB issued guidance clarifying the revenue recognition and measurement issues for grants, contracts, and similar arrangements, ASU Topic 958. Government grants and contracts are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. The Company has evaluated its grant with NIH and contract with BARDA and determined they are non-exchange transactions and fall withing the scope of ASU 958, and revenue should be recognized in accordance with Topic 958 guidance. Accordingly, the Company recognizes revenue from its grant and contract in the period during which the related costs are incurred, provided that the conditions under which the grants and contracts were provided have been met and only perfunctory performance obligations are outstanding. Licensing Agreement Pursuant to the Adapt Agreement, the Company provided a global license to develop and commercialize the Company’s intranasal naloxone opioid overdose reversal treatment, now known as NARCAN®. On December 15, 2014, the Company entered into a License Agreement with Adapt. Pursuant to the License Agreement, we provided a global license to develop and commercialize our intranasal naloxone opioid overdose reversal treatment, now known as NARCAN®. In addition, on the SWK Closing Date, in connection with the SWK Purchase Agreement, as disclosed below, we entered into the Adapt Amendment which amends the terms of the License Agreement relating to the grant of a commercial sublicense outside of the United States and diligence efforts for commercialization of our Opioid Overdose Reversal Treatment Product. Under the terms of the Adapt Amendment, Adapt is required to use commercially reasonable efforts to commercialize the Opioid Overdose Reversal Treatment Product in the United States In the event that Adapt wishes to grant a commercial sublicense to a third party in the European Union or the United Kingdom, we have agreed to negotiate an additional amendment to the License Agreement to include reduced financial terms with respect to the commercial sublicense. The Company also receives payments upon reaching various sales and regulatory milestones, as well as royalty payments for commercial sales of NARCAN® generated by Adapt. During the year ended December 31, 2018 and the five months ended December 31, 2017, the Company recognized royalty and milestone revenue of $13.3 million and $11.7 million , respectively. Interest in Treatments With respect to investments in interests in treatments, if an agreement provides an option that allows the investor in the treatment to convert an interest in a treatment into shares of Common Stock of the Company, then revenue is deferred until such time that the option expires or milestones are achieved that eliminate the investor’s right to exercise the option. Upon expiration of the exercise option, the deliverables of the arrangement are reviewed and evaluated under ASC 606. In the event the investor chooses to convert interests into shares of Common Stock, that transaction will be accounted for similar to a sale of shares of Common Stock for cash. Sale of Royalties Under the SWK Purchase Agreement, the Company received an upfront purchase price of $13,750,000 less $40,000 of legal fees, and recognized an additional $3,750,000 when certain milestones were achieved during the fiscal year ended July 31, 2017. During the fiscal year ended July 31, 2017, the Company recognized total proceeds of $17,460,000 as revenue associated with the SWK Purchase Agreement immediately as a result of (i) the executed agreement constituting persuasive evidence of an arrangement, (ii) the Company having no current or future performance obligations, (iii) the total consideration being fixed and known at the time of its execution and there being no rights of return, and (iv) the cash having been received and non-refundable. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. In June 2018, the FASB issued ASU No. 2018-07, "Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting," ("ASU 2018-07"), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. ASU 2018-07 is effective for financial statements issued for annual periods beginning after December 15, 2018, and for the interim periods therein. The adoption of ASU 2018-07 is not expected to have a significant impact on the Company’s consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, "Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract" (ASU No. 2018-15). The new standard describes the accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA). Under the new guidance, customers will assess if a CCA includes a software license and if a CCA does include a software license, implementation and set-up costs will be accounted for consistent with existing internal-use software implementation guidance. Implementation costs associated with a CCA that does not include a software license would be expensed to operating expenses. The standard also provides classification guidance on these implementation costs as well as additional quantitative and qualitative disclosures. The standard is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim periods. Entities can choose to adopt the new guidance prospectively or retrospectively. The Company is assessing this standard and currently believes it will not have any material impact on the consolidated financial statements. In 2018, the FASB issued ASU No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This new standard permits entities to reclassify to retained earnings the tax effects stranded in accumulated other comprehensive income ("AOCI") as a result of U.S. tax reform. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company has evaluated the impact and timing of the this standard and has concluded it will not impact the consolidated financial statements. In 2017, the FASB issued ASU No. 2017-07, Compensation-Retirement Benefits (Topic 715), Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.The standard requires that an employer report the service cost component in the same line items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside of operating profit. The amendments in this update are effective for public business entities for annual periods beginning after December 15, 2017, including interim periods within those annual periods. The Company adopted this ASU effective January 1, 2018 and has concluded it will not impact the consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, " Leases" (Topic 842) The new standard requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right-of-use ("ROU") model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The standard is effective on January 1, 2019, with early adoption permitted. The Company adopted the new standard on January 1, 2019, and there is no impact from the adoption of this standard as the current office leases are less than 12 months. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash” ("ASU 2016-18”). The update is effective for fiscal years beginning after December 15, 2017, including interim reporting periods within those fiscal years. The purpose of Update No. 2016-18 is to clarify guidance and presentation related to restricted cash in the statement of cash flows. The amendment requires beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include cash and cash equivalents as well as restricted cash and restricted cash equivalents. The Company adopted this ASU effective January 1, 2018 and has concluded it did not have a material impact on its consolidated financial statements. In October 2016, the FASB issued updated guidance related to the recognition of income tax consequences of an intra-entity transfer of an asset other than inventory. This guidance is effective for the first quarter of tax year 2018. The Company has adopted the guidance and determined that there is no impact on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230)” (“ASU 2016-15”), which seeks to reduce the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. For public entities, Update 2016-15 becomes effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this ASU effective January 1, 2018 and has concluded it did not have a material impact on its consolidated financial statements. In March 2016, the FASB issued Accounting Standards Update No. 2016-09, “ Compensation - Stock Compensation (Topic 718) : Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for financial statements issued for fiscal years beginning December 15, 2016, and interim periods within those fiscal years. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. The guidance provided an entity-wide accounting policy election to account for forfeitures as they occur. The Company has elected to record forfeitures as they occur. The Company has evaluated the requirements of the new guidance and has determined that the impact is not material to its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes ("ASU 2017-17") to simplify the presentation of deferred income taxes. ASU 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015-17 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company has adopted the provisions of Update 2016-15 and determined that there is no impact on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, " Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern ." The amendments in this ASU are intended to provide guidance on the responsibility of reporting entity management. Specifically, this ASU provides guidance to management related to evaluating whether there is substantial doubt about the reporting entity’s ability to continue as a going concern and about related financial statement note disclosures. Although the presumption that a reporting entity will continue to operate as a going concern is fundamental to the preparation of financial statements, prior to the issuance of this ASU, there was no guidance in United States generally accepted accounting principles (United States GAAP) related to the concept. Due to the lack of guidance in United States GAAP, practitioners and their clients often faced challenges in determining whether, when, and how a reporting entity should disclose the relevant information in its financial statements. As a result, the FASB issued this guidance to require management evaluation and potential financial statement disclosures. This ASU is effective for financial statements with periods ending after December 15, 2016. The Company adopted the ASU during 2017 and performed going concern evaluations for its 2018 and 2017 year-end financial statements. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its consolidated financial statements.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions The Company uses office space provided by Dr. Phil Skolnick, the Company’s Chief Scientific Officer, free of charge. On March 31, 2017, Dr. Michael Sinclair and Dr. Roger Crystal, the Company’s Chief Executive Officer, each voluntarily entered into separate employment agreement acknowledgements whereby they elected to forfeit, unconditionally and irrevocably, $175,498 and $586,328 , respectively, of certain owed amounts pursuant to their respective existing employment agreements, representing 35% of the total compensation currently owed to each of Dr. Sinclair and Dr. Crystal on such date. As the debt forgiven was owed to a related party, the Company recognized the amount forgiven as an equity transaction recorded in additional paid-in capital. Furthermore, on March 31, 2017, pursuant to their respective employment agreement acknowledgements, Dr. Sinclair and Dr. Crystal each voluntarily elected to forfeit, unconditionally and irrevocably, 680,000 and 825,000 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company underlying stock options and warrants previously issued by the Company, respectively, representing approximately 55% of the total number of options and warrants previously issued by the Company to each of Dr. Sinclair and Dr. Crystal. During the fiscal year ended July 31, 2017, the Company did no t borrow any funds from related parties, nor did it have any outstanding related party debt and/or accrued and unpaid interest owed to related parties as of July 31, 2017.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2018
Receivables [Abstract]
Accounts Receivable	Accounts Receivable As of December 31, 2018 the Company had accounts receivable of $4,489,317 of which $4,484,433 relates to royalty revenue from the sales of NARCAN®. As of December 31, 2017, the Company determined that the Capped Royalty Amount provided in the SWK Agreement had been met (see Note 2 - Liquidity and Financial Condition). As a result, 90% of any succeeding milestone payments and royalties due from Adapt/EBS will revert to the Company while the remaining 10% will be paid to SWK directly by Adapt/EBS. As of December 31, 2017, the Company recognized accounts receivable of $ 11,696,676 , which is equivalent to 90% of the milestone payments and royalties earned during the five months ended December 31, 2017. The Company had accounts receivable of $3,750,000 as of July 31, 2017, with the entire amount being related to the Earn Out Milestone from SWK. As provided under the Company’s agreement with SWK, the Company was to receive a milestone payment in the amount of $3,750,000 if Adapt had received in excess of $25,000,000 of cumulative Net Sales for any two consecutive fiscal quarters during the period from October 1, 2016 through September 30, 2017 from the sale of NARCAN®. This milestone was achieved as of July 31, 2017, therefore the Company recorded the $3,750,000 as an account receivable, with the actual cash payment being received by the Company on August 9, 2017.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets As of December 31, 2018, the Company had approximately $268 thousand recorded as prepaid expenses and other current assets. Of this amount approximately $74 thousand is for research and development supplies related to product development work being performed by Renaissance Lakewood, LLC ("Renaissance") (see Note 10 - Commitments), and the remaining $194 thousand is for prepaid expenses such as rent, insurance, and software licenses. As of December 31, 2017, the Company had approximately $ 0.7 million recorded as prepaid expenses and other current assets. Approximately $0.4 million was related to a deposit made by the Company to Renaissance in August 2017. As provided under the agreement with Renaissance, the Company was obligated to make this deposit to fund the initial costs of the product development work to be performed by Renaissance on behalf of the Company. As of December 31, 2017, no work had been performed, nor had any costs been incurred, in relation to this project. During the five months ended December 31, 2017, the Company purchased approximately $0.1 million of research and development supplies related to the above referenced product development work being performed by Renaissance. As provided under the agreement with Renaissance, the Company is obligated to pay for all supplies and materials that are needed to complete this product development work. These supplies were delivered on October 16, 2017 and approximately $25 thousand in supplies have been used as of December 31, 2018. The remaining balance consists primarily of prepaid expenses such as rent, insurance, and software licenses. The Company had recorded approximately $0.2 million as prepaid expenses and other current assets at July 31, 2017 that consists primarily of prepaid expenses such as rent, insurance, and software licenses.

Deferred Financing Costs

Deferred Financing Costs	12 Months Ended
	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Financing Costs	Deferred Financing Costs During the five months ended December 31, 2017, the Company incurred approximately $0.2 million of legal, accounting, and filing fees related to the Company's fund raising efforts. The Company recorded the $0.2 million as deferred financing costs as of December 31, 2017. These expenses were offset against net proceeds received from the Company's financings during 2018.

Deferred Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2018
Deferred Revenue Disclosure [Abstract]
Deferred Revenue	Deferred Revenue On December 17, 2013, the Company entered into an agreement with an investor, Potomac, and subsequently received additional funding totaling $250 thousand for use by the Company for any purpose. In exchange for this funding, the Company agreed to provide the investor with a 0.5% interest in the Company’s BED treatment product (the “BED Treatment Product”) and pay the investor 0.5% of the BED Net Profit in perpetuity (the “2013 0.5% Investor Interest”). “BED Net Profit” is defined as the pre-tax profit generated from the BED Treatment Product after the deduction of all expenses incurred by and payments made by the Company in connection with the BED Treatment Product, including but not limited to an allocation of Company overhead. If the BED Treatment Product was not approved by the FDA by December 17, 2016, the investor had a 60 -day option to exchange its entire 0.5% Investor Interest for 31,250 shares of Common Stock of the Company. On February 17, 2017, the investor’s option to receive the shares of Common Stock terminated by its terms, which resulted in the Company beginning to recognize revenue in relation to this agreement in February 2017. The Company estimates that sufficient research and development will be completed by December 31, 2020 to allow the Company to advance the program into final registration studies. Therefore, the Company recognized revenue on a straight-line basis over the expected completion date. During the year ended December 31, 2018, the five months ended December 31, 2017 and the year ended July 31, 2017, the Company recognized approximately $58 thousand , $36 thousand and $39.9 thousand of revenue relating to the agreement, respectively. On September 17, 2014, the Company entered into an agreement with an investor, Potomac, and subsequently received funding totaling $500 thousand for use by the Company for any purpose. In exchange for this funding, the Company agreed to provide the investor with a 1.0% interest in the Company’s BED Treatment Product and pay the investor 1.0% of the BED Net Profit generated from the BED Treatment Product in perpetuity (the “ 1.0% Investor Interest”). “BED Net Profit” is defined as the pre-tax profit generated from the BED Treatment Product after the deduction of all expenses incurred by and payments made by the Company in connection with the BED Treatment Product, including but not limited to an allocation of Company overhead. If the BED Treatment Product is not approved by the FDA by September 17, 2017, the investor will have a 60 -day option to exchange its entire 1.0% Investor Interest for 62,500 shares of Common Stock of the Company. On November 15, 2017, the investor’s option to receive the shares of Common Stock terminated by its terms, which resulted in the Company beginning to recognize revenue in relation to this agreement in November 2017. The Company estimates that sufficient research and development will be completed by December 31, 2020 to allow the Company to advance the program into final registration studies. Therefore, the Company recognized revenue on straight-line basis over the expected completion date. During the year ended December 31, 2018 and the five months ended December 31, 2017, the Company recognized approximately $156,863 and $29,400 of revenue related to this agreement. The Company recognized no revenue for the fiscal year ended July 31, 2017. On July 20, 2015, the Company entered into an agreement with an investor, Potomac, and subsequently received funding from an individual investor in the amount of $250 thousand for use by the Company for any purpose. In exchange for this funding, the Company agreed to provide the investor with a 0.5% interest in the BED Net Profit (the “2015 0.5% Investor Interest”) generated from the BED Treatment Product in perpetuity. The investor also has rights with respect to the 2015 0.5% Investor Interest if the BED Treatment Product is sold or the Company is sold. If the product is not introduced to the market and not approved by the FDA or an equivalent body in Europe and not marketed by July 20, 2018, the investor will have a 60 -day option to exchange the 2015 0.5% Investor Interest for 25,000 shares of Common Stock of the Company. The Investor did not elect to exchange their interest for shares of Common Stock as described above and the Company commenced recognizing revenue in September 2018. For the year ended December 31, 2018 the Company recognized $35,714 of revenue related to this agreement. On September 22, 2015, the Company received a $1.6 million commitment from the Foundation which later assigned its interest to Valour in October 2016, from which the Company had the right to make capital calls from the Foundation for the research, development, any other activities connected to the Company’s opioid antagonist treatments for addictions and related disorders that materially rely on certain studies funded by the Foundation’s investment, excluding the Opioid Overdose Reversal Treatment Product (the “Certain Studies Products”), certain operating expenses, and any other purpose consistent with the goals of the Foundation. In exchange for funds invested by the Foundation, Valour currently owns 2.1333% interest in the Certain Studies Products Net Profit (the “ 2.1333% Interest”). The “Certain Studies Net Profit” is defined as any pre-tax revenue received by the Company that was derived from the sale of the Certain Studies Products less any and all expenses incurred by and payments made by the Company in connection with the Certain Studies Products, including but not limited to an allocation of Company overhead based on the proportionate time, expenses and resources devoted by the Company to Certain Studies Product-related activities, which allocation shall be determined in good faith by the Company. Valour also has rights with respect to its up to a 2.1333% Interest if the Certain Studies Product is sold or the Company is sold. Additionally, the Company may buy back, in whole or in part, the 2.1333% Interest from Valour within 2.5 years or after 2.5 years of the initial investment at a price of two times or 3.5 times, respectively, the relevant investment amount represented by the interests to be bought back. If an aforementioned treatment is not introduced to the market by September 22, 2018, Valour will have a 60 -day option to exchange its 2.1333% Interest for shares of the Common Stock of the Company at an exchange rate of one-tenth of a share for every dollar of its investment. On October 2, 2015, December 23, 2015, and May 28, 2016, the Company made capital calls of approximately $618 thousand , $715.5 thousand , and $266.5 thousand from the Foundation in exchange for 0.824% , 0.954% and 0.355333% interests in the aforementioned treatments, respectively. The Company will defer recording revenue until such time as Valour’s option expires or milestones are achieved that eliminates Valour’s right to exercise the option. Upon expiration of the exercise option, the deliverables of the arrangement will be reviewed and evaluated under Accounting Standards Codification (ASC) 606. In the event Valour chooses to exchange its 2.1333% Interest, in whole or in part, for shares of Common Stock of the Company, that transaction will be accounted for similar to a sale of shares of Common Stock for cash. During September 2018 Valour elected to exchange its interest for shares of Common Stock and accordingly the Company issued 160,000 shares of its Common Stock to Valour. On April 17, 2018, the Company was awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse, ("NIDA"). The grant provides the Company with additional resources for the ongoing development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. The grant includes approximately $2.6 million to be funded for the period ending March 31, 2019, with the balance to be funded over the subsequent two years, subject to available funds and satisfactory progress on the development of OPNT003. Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. The Company recognizes revenues from grants in the period during which the related costs were incurred, provided that the conditions under which the grants were provided had been met and only perfunctory obligations were outstanding. During the year ended December 31, 2018 the Company received cash of $1.0 million and recognized revenue of $432 thousand related to this grant. The following is a summary of the Company’s deferred revenue activity for the year ended December 31, 2018, the five months ended December 31, 2017 and the year ended July 31, 2017: (in thousands) NIH Grant BED Other Total Balance as of July 31, 2016 $ — $ 1,000 $ 1,600 $ 2,600 Recognized as revenue — (39 ) — (39 ) Balance as of July 31, 2017 — 961 1,600 2,561 Recognized as revenue — (66 ) — (66 ) Balance as of December 31, 2017 — 895 1,600 2,495 Cash Received NIH 1,000 — — 1,000 Converted to Equity — — (1,600 ) (1,600 ) Recognized as revenue (432 ) (251 ) — (683 ) Balance as of December 31, 2018 $ 568 $ 644 $ — $ 1,212 As of December 31, 2018, the Company had recorded approximately $ 1,212 thousand of its deferred revenue as a current liability because the Company expects to recognize that amount as revenue during the next 12 months. Current and long-term deferred revenue are detailed in the following table: Deferred Revenue (in thousands) NIH Grant BED Other Total Current portion $ 568 $ 644 $ — $ 1,212 Long-term portion — — — — Total $ 568 $ 644 $ — $ 1,212

License Fee Payable

License Fee Payable	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
License Fee Payable	License Fee Payable On February 28, 2018, the Company was notified that Adapt, now a Subsidiary of Emergent BioSolutions ("EBS"), had entered into a license agreement with a Third Party (as defined in the License Agreement) with regard to one or more patents pursuant to which Adapt invoked its right under Section 5.5 of the License Agreement, dated as of December 15, 2014, by and between the Company and Adapt, as amended (the "License Agreement"), to offset 50% of certain payments paid to such Third Party from the amounts payable by Adapt to the Company under the License Agreement and SWK under the SWK Purchase Agreement. On March 1, 2018, the Company received net milestone payments of $6.1 million , which was net of 50% of a license fee payment Adapt made to the Third Party. Adapt reduced such milestone payment by $6.25 million pursuant to Section 5.5 of the License Agreement. The portion of the milestone payment that the Company would have otherwise received was reduced by $5.6 million . As provided in Amendment No. 2 to the License Agreement, which the parties entered into on March 18, 2019 (see Note 17, Subsequent Events), Adapt has made has made and will in the future make payments to the Third Party Licensee and will be allowed to reduce the royalties and milestones that the Company would be due under the License Agreement by a maximum of $9.0 million in relation to such payments. Under the SWK Purchase Agreement, the Company retains 90% of the royalties payable under the License Agreement, with SWK entitled to 10% . The maximum amount payable by the Company is therefore $8.1 million (90% of $9 million), of which the Company has recorded $5.4 million as a current liability and $2.7 million as a long-term liability at December 31, 2018. As provided in Amendment No. 2, Adapt will be allowed to reduce the royalties and milestones that the Company would be due under the License Agreement during the year ending December 31, 2019 by a maximum of $1.8 million each quarter. As provided in the License Agreement, if Net Narcan Sales (as defined in the License Agreement) exceed $200 million in any calendar year, the Company and SWK will be due a milestone of $15.0 million . Under Amendment No. 2, if this $15.0 million milestone becomes payable to the Company and SWK, Adapt may deduct $2.7 million from the $13.5 million (90% of $15.0 million) milestone payable to the Company.

Royalty Payable

Royalty Payable	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Royalty Payable	Royalty Payable The Company entered into various agreements and subsequently received funding from investors for use by the Company for the research and development its OORT Product. In exchange for this funding, the Company agreed to provide investors with interest in the OORT Net Profit generated from its OORT Product in perpetuity. At December 31, 2018 and 2017, the Company determined an OORT Net Profit as a result of NARCAN® sales by Adapt. There was no OORT Net Profit prior to December 31, 2017. The following table sets forth the royalty payable to certain investors as of December 31, 2018 and December 31, 2017: (in thousands) Net Profit % December 31, 2018 December 31, 2017 Potomac 10.2% $ 422 $ 860 LYL 5.0% 206 421 Welmers 1.5% 62 127 Foundation 6.0% 248 — Pendergast 1.0% 60 — Royalty payable 23.7% $ 998 $ 1,408

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments The Company has entered into various agreements related to its business activities. The following is a summary of the Company’s commitments: a. On December 18, 2014, the Company entered into a consulting agreement (the "2014 Agreement") with Torreya Partners LLP ("Torreya"), a financial advisory firm, under which Torreya agreed to provide financial advisory services with regard to a licensing agreement. The Company is also required to pay an additional fee equivalent to 3.75% of all amounts received by the Company in excess of $3.0 million , in perpetuity. Total fees incurred by the Company to this consultant pursuant to this agreement during the fiscal year ended July 31, 2017 amounted to approximately $963.6 thousand . On April 25, 2016, the Company entered into a consulting agreement with Torreya, under which Torreya agreed to provide financial advisory services for financing activities. In exchange for these services, the Company is required to pay a fee on all funding received by the Company as a result of assistance provided by the consultant. Torreya’s fee will be equal to 5% of gross funding received by the Company up to $20 million plus 3.5% of any proceeds received in excess of $20 million . Total fees incurred by the Company to this consultant pursuant to this agreement during the fiscal year ended July 31, 2017 amounted to $687.5 thousand . As of July 31, 2017, the Company had recorded an accrued liability of approximately $928.5 thousand relating to fees owed to Torreya. On September 8, 2017, the Company and Torreya entered into the Supplemental Engagement Letter to provide financial advisory services with respect to the licensing of the intellectual and property rights to develop and commercialize certain products with Adapt Pharma Operations Limited, an Ireland based pharmaceutical company ("Adapt"). The revised engagement amends total consideration as follows: (i) an aggregate of $300 thousand in cash payments to be paid by the Company to Torreya in three equal installments over a 16 -month period; (ii) shares of Common Stock, equal to an aggregate value of $300 thousand , to be issued by the Company to Torreya in three equal installments over a 16 -month period; (iii) if the Earn Out Milestone Payment is paid under the SWK Purchase Agreement, approximately $140.6 thousand , or 3.75% of the Earn Out Milestone Payment (as defined in the SWK Purchase Agreement), shall be paid by the Company to Torreya within 15 days of the date that the Earn Out Milestone (as defined in the SWK Purchase Agreement) has been paid to the Company; (iv) once SWK has received the Capped Royalty Amount, if the Earn Out Milestone Payment (as defined in the SWK Agreement) is paid, Torreya shall receive 3.375% of the Total Consideration (as defined in the 2014 Agreement) received thereafter or 3.5625% of the Total Consideration received thereafter if no generic version of NARCAN is commercialized prior to the six th anniversary of the Closing Date (as defined in the SWK Agreement) as per the terms of the SWK Agreement; and (v) once SWK has received the Capped Royalty Amount, if the Earn Out Milestone Payment has not been paid, Torreya shall receive 3.45525% of the Total Consideration received thereafter or 3.602625% of the Total Consideration received thereafter if no generic version of NARCAN® is commercialized prior to the six th anniversary of the Closing Date as per the terms of the SWK Purchase Agreement. Payments made by the Company in the form of shares of Common Stock will be a defined number of shares calculated based upon the average closing price of the Common Stock for the ten trading days prior to the relevant date for the payment. On September 23, 2017, the Company issued 3,283 shares of its Common Stock to Torreya as payment for $100 thousand of fees owed by the Company to Torreya. The Company valued these shares at $40.58 per share, or approximately $133 thousand in the aggregate, which represents the closing price of the Company's Common Stock on September 22, 2017. The Company also paid Torreya approximately $240.6 thousand in cash in September 2017 as payment for fees owed. On December 22, 2017, the Company issued 3,455 shares as payment for $100 thousand of fees owed by the Company to Torreya. The Company valued these shares at $24.95 per share, or approximately $81 thousand in the aggregate, which represents the closing price of the Company's Common Stock on December 22, 2017. The Company also paid Torreya $100 thousand in cash in December 2017 as payment for fees owed. Both the $200 thousand of fees paid via the issuance of Common Stock and the $340.6 thousand of fees paid in cash had been recorded as accrued liabilities as of July 31, 2017. During the five-month period ended December 31, 2017, the Company incurred approximately $439 thousand in aggregate fees related to Torreya. As of December 31, 2017, the Company had an accrued liability of $639 thousand owed to Torreya. During the year ended December 31, 2018, the Company incurred approximately $447 thousand in aggregate fees related to Torreya. In addition during December 2018 the Company paid Torreya $100 thousand in cash and issued 6,498 shares of Common Stock representing a total of $200 thousand of fees owed by the Company to Torreya which had been recorded as accrued liability as of December 31, 2017. As of December 31, 2018 the Company has an accrued liability of $151 thousand owed to Torreya. b. On November 19, 2015, the Company issued 14,327 shares of unregistered Common Stock upon the execution of a binding letter of intent to agree to negotiate and enter into an exclusive license agreement and collaboration agreement (“LOI”) with a pharmaceutical company with certain desirable proprietary information. The shares issued in this transaction were valued using the stock price at issuance date and amounted to approximately $120.3 thousand . Pursuant to the LOI, the Company is obligated to issue up to an additional 92,634 shares of unregistered Common Stock upon the occurrence of various milestones. A total of 3,582 shares had been issued as of July 31, 2016 due to achievement of certain milestones. On November 10, 2016, the Company issued an additional 14,327 shares of the unregistered Common Stock pursuant to the LOI. The shares issued in this transaction were valued using the stock price at issuance date and amounted to approximately $85.1 thousand . On March 16, 2017, the Company issued an additional 10,745 shares of unregistered Common Stock pursuant to the LOI. The Company was obligated to issue these shares upon the one year anniversary of receipt by the Company of a milestone payment from Adapt for the first commercial sale of the Company’s product, NARCAN®, in the U.S. The shares issued on March 16, 2017 were valued on the date of issuance using the March 16, 2017 closing price of the Company’s Common Stock of $7.75 per share, which resulted in an aggregate value of approximately $83.3 thousand . The Company expensed the entire $83.3 thousand as non-cash expense during the fiscal year ended July 31, 2017. There were no share issuances, no r any expenses incurred, by the Company in relation to this LOI during the five months ended December 31, 2017. As of March 31, 2018, the Company was required to issue an additional 37,866 shares of its unregistered Common Stock pursuant to the LOI. The Company was obligated to issue these shares on the receipt of cumulative royalty payments of $2 million from Adapt and milestone payments from Adapt with respect to first achieving the milestones of the first $30 million , $40 million , $55 million and $75 million of Net NARCAN® Sales. The shares that were issuable as of March 31, 2018, were valued using the March 29, 2018 closing stock price of the Company's Common Stock of $19.18 per share, which resulted in an aggregate value of approximately $726 thousand . On April 19, 2018 the Company issued 37,866 shares of Common Stock. For the year ended December 31, 2018 the Company recorded total non-cash expense of $776 thousand , of which $726 thousand was recorded to research and development expense and $ 50 thousand was recorded to loss on settlement of liability in other expense. c. In October 2016, the Company in-licensed a heroin vaccine from Walter Reed Army Institute of Research ("WRAIR"). In consideration for the license the Company agreed to pay a royalty of 3% of net sales if the Company commercializes the vaccine, or 4% if the vaccine is sublicensed. In addition, the Company agreed to pay a minimum annual royalty of $10 thousand , as well as fixed payments of up to approximately $715.7 thousand if all of the specified milestones are met. During the five months ended December 31, 2017, the Company paid $60 thousand in cash to WRAIR, of which $50 thousand was a non-recurring "execution" fee and the remaining $10 thousand was the minimum annual royalty for the period of September 2017 through August 2018. The $10 thousand minimum annual royalty was recorded as a prepaid expense and is being expensed at the rate of $833 per month, beginning in September 2017 and ending in August 2018. d. The Company has a Sublease with Standish Management, LLC to sublease office space on a month-to-month basis, located at 201 Santa Monica Boulevard, Suite 500, Santa Monica, CA 90401, which is the Company's headquarters. The Company also has an Office Service Agreement to lease office space at 83 Baker Street, London, England, W1U 6AG. Effective May 31, 2018 either party is able to terminate the Office Service Agreement by providing three months advance written notice of termination. During the year ended December 31, 2018, the five months ended December 31, 2017, and the year ended July 31, 2017 the Company incurred approximately $321 thousand , $150 thousand , and $123 thousand , respectively of rent expense. e. On June 1, 2017 (the “LYL Effective Date”), the Company entered into an amendment with LYL (the “LYL Amendment”) to the Amended and Restated Consulting Agreement, dated October 25, 2016 and effective as of July 17, 2013 (the “LYL Agreement”). Pursuant to the LYL Amendment, LYL granted the Company certain buyback provisions that have expired as of December 31, 2018. In consideration for LYL entering into the LYL Amendment, upon the Company's receipt after the LYL Effective Date of at least $3 million from (i) SWK under the SWK Purchase Agreement and/or (ii) Adapt under the Adapt Agreement, fifty percent of all actual amounts received by the Company from SWK will be used in determining the Net Profit (as defined in the LYL Agreement). f. On June 22, 2017, the Company entered into a license agreement (the "License Agreement") and a related supply agreement (the “Supply Agreement”) with Aegis Therapeutics LLC ("Aegis") pursuant to which the Company was granted an exclusive license (the “License”) to Aegis’ proprietary chemically synthesizable delivery enhancement and stabilization agents, including, but not limited to, Aegis’ Intravail® absorption enhancement agents, ProTek® and HydroGel® (collectively, the “Technology”) to exploit (a) the Compounds (as such are defined in the License Agreement) and (b) a product containing a Compound and formulated using the Technology (“Aegis Product”), in each case of (a) and (b) for any and all purposes. The License Agreement restricts the Company's ability to manufacture any Aegis excipients included in the Technology (“Excipients”), except for certain instances of supply failure, supply shortage or termination of the Supply Agreement, and the Company shall obtain all supply of such Excipients from Aegis under the Supply Agreement. The License Agreement also restricts Aegis’s ability to compete with the Company worldwide with respect to the Exploitation (as defined in the License Agreement) of any therapeutic containing a Compound or derivative or active metabolite of a Compound without the Company's prior written consent. The effective date of the License Agreement and the Supply Agreement is January 1, 2017. As consideration for the grant of the License, the Company paid Aegis two immaterial upfront payments, of which the Company paid 50% by issuing the Company's Common Stock to Aegis, with the number of shares issued equal to 75% of the average closing price of the Company's Common Stock over the 20 trading days preceding the date of payment. The License Agreement also provides for (A) additional developmental milestone payments for each Product containing a different Compound equal to up to an aggregate of $1.8 million , (B) additional commercialization milestone payments for each Aegis Product containing a different Compound equal to up to an aggregate of $5.0 million , and (C) single low digit royalties on the Annual Net Sales (as defined in the License Agreement) of all Aegis Products during the Royalty Term (as defined in the License Agreement) according to a tiered royalty rate based on Annual Net Sales of the Aegis Products by the Company, the Company's sublicensees and affiliates. The Company shall also pay to Aegis a sublicense fee based on a sublicense rate negotiated in good faith by the parties. The License Agreement contains customary representations and warranties, ownership, patent rights, confidentiality, indemnification and insurance provisions. The License Agreement shall expire upon the expiration of the Company's obligation to pay royalties under such License Agreement; provided, however, that the Company shall have the right to terminate the License granted on a product-by-product or country-by-country basis upon 30 days ’ prior written notice to Aegis. Under the terms of the Supply Agreement, Aegis shall deliver to the Company any preclinical, clinical and commercial supply of the Excipients, which Aegis sources from various contract manufacturers. The Supply Agreement has a term of 20 years but shall terminate automatically in the event of expiration or termination of the License Agreement or at any time upon the written agreement of both parties. The Supply Agreement contains customary provisions relating to pricing for such materials, forecasts, delivery, inspection, indemnification, insurance and representations, warranties and covenants. The Supply Agreement includes technology transfer provisions for the transfer of all materials and know-how specific to the manufacturing of the Excipients that is necessary or useful for the Company to manufacture such Excipients. The Company does not have the right to manufacture such Excipients except in the event that Aegis is unable to supply and sell any portion of the material to the Company (subject to a 60 -day cure period). For the year ended December 31, 2018, the five months ended December 31, 2017 and the year ended July 31, 2017, the Company recorded $350 thousand , $150 thousand and $200 thousand , respectively in expense associated with the License Agreement. g. On July 14, 2017, Renaissance Lakewood, LLC (“Renaissance”) and the Company entered into a Research and Development Agreement (the “Renaissance Agreement”). Under the Renaissance Agreement, Renaissance will perform product development work on a naltrexone multi-dose nasal product for the treatment of alcohol use disorder pursuant to the terms set forth in a proposal agreed upon by the parties. The Company will bear the costs of all development services, including all raw materials and packaging components, in connection with the performance of the development work under the Renaissance Agreement and in accordance with financials agreed upon through the proposal. Renaissance will conduct quality control and testing, including non-stability, stability, in-use, raw material, and packaging component testing as part of the services provided to the Company under the Renaissance Agreement. The Company will own all formulations provided to Renaissance and any formulations developed in connection with the Renaissance Agreement. Renaissance will own all know-how developed in connection with the performance of the services that is not solely related to a product. The Company has the right to seek patent protection on any invention or know-how that relates solely to a product developed under the Renaissance Agreement or any our formulation, excluding general manufacturing or product development know-how of Renaissance. The Renaissance Agreement is effective until terminated by either party in accordance with its terms. The Company or Renaissance may terminate the project under a proposal to the Renaissance Agreement due to unforeseen circumstances in the development. The Renaissance Agreement may be terminated by the Company, with or without cause, upon 45 days written notice. There are also mutual customary termination provisions relating to uncured breaches of material provisions. See Note 6 - Prepaid Expenses and Other Current Assets. h. On September 5, 2017, the Company accepted, effective September 11, 2017 (the “Separation Date”), the resignation of Kevin Pollack as (i) the Company’s Chief Financial Officer, Treasurer and Secretary, and (ii) a director of Opiant Pharmaceuticals UK Limited, a wholly owned subsidiary of the Company. On September 5, 2017, the Company and Mr. Pollack entered into a Separation Agreement and General Release (the “Separation Agreement”), with such agreement becoming effective on September 12, 2017 (the "Separation Agreement Effective Date"), which represented the date on which Mr. Pollack's seven -day revocation period expired. Pursuant to the terms of the Separation Agreement, Mr. Pollack received (i) a payment equal to approximately $1.13 million relating to certain accrued obligations, payable in a cash lump sum within three business days following the Separation Agreement Effective Date; and (ii) a separation payment equal to approximately $1.44 million , payable in one or two installments in accordance with the terms set forth therein. Mr. Pollack also retained previously granted options to purchase, in the aggregate, 948,000 shares of Common Stock of the Company, which options are fully vested and exercisable. Except as set forth in the Separation Agreement, all other options held by Mr. Pollack were forfeited. Additionally, for a period of no more than 12 months following the Separation Date, Mr. Pollack will cooperate as an adviser with the Company in connection with matters arising out of Mr. Pollack’s service with the Company, in accordance with the terms set forth in the Separation Agreement. During the five months ended December 31, 2017, the Company paid Mr. Pollack approximately $1.61 million in cash pursuant to the terms of the Separation Agreement. In addition, as of December 31, 2017, the Company has recorded an accrued liability of approximately $962 thousand . During September 2018, the Company made the final payment due to Mr. Pollack. i. On September 7, 2018, the Company entered into a Development Agreement ("Development Agreement") and an Agreement for Reimbursement of Capital Expenditure and Service Fees ("Reimbursement Agreement") with Aesica Queenborough Limited ("Aesica"), a wholly owned subsidiary of Consort Medical plc, related to the Company’s product OPNT003 (intranasal nalmefene), a potent long acting opioid antagonist for the treatment of opioid overdose. As part of the Development Agreement, Aesica and Bespak, wholly owned subsidiaries of Consort, will supply the Company with clinical samples and registration batches for the purpose of performing clinical studies and obtaining regulatory approvals. Further, as part of the Development Agreement, the Company and Aesica agreed that, upon approval by the U.S. FDA, Aesica and Bespak will manufacture and supply the commercial device for the Company upon mutually agreed terms. Under the terms of the Reimbursement Agreement, the Company has agreed to reimburse Aesica for certain service, tooling, equipment and facility alteration expenses incurred by Aesica under certain circumstances, including termination of the Development Agreement and the failure to complete a definitive manufacturing and supply agreement. Contingencies The Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. If any legal matter, that may arise, were resolved against the Company in a reporting period for amounts in excess of management’s expectations, the Company’s would reflect any potential claim in the consolidated financial statements for that reporting period.

Stockholder's Equity

Stockholder's Equity	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholder's Equity Common Stock During the year ended December 31, 2018 During the year ended December 31, 2018, the Company issued 50,497 shares of its Common Stock in relation to the cashless exercise of stock options that were granted outside of the Company's 2017 Long-Term Incentive Stock Plan (the "2017 Plan"). A total of 95,000 stock options were exercised with exercise prices between $7.25 and $10.00 per share. During the year ended December 31, 2018, the Company issued 3,400 shares of its Common Stock as a result of the exercise of stock purchase warrants with an exercise price of $10.00 per share for total proceeds of $34,000 . During the year ended December 31, 2018 the Company issued 38,166 shares of its Common stock with an aggregate value of $782 thousand for services provided to the Company. On September 5, 2018, the Company also issued 160,000 shares of Common Stock to Valour Fund, LLC, as a result of Valour's exercise of its option to exchange its interest in certain product revenues for Common Stock of the Company. On December 18, 2018, the Company issued 6,498 shares of its Common Stock to Torreya. These shares were issued as payment in full for a $100 thousand accrued liability owed by the Company to Torreya pursuant to that certain Supplemental Engagement Letter between the Company and Torreya, dated September 8, 2017 (the "Supplemental Engagement Letter"). During October 2017 the Company entered into a Controlled Equity Offering sales agreement (the "Sales Agreement") with Cantor Fitzgerald & Co., as agent ("Cantor Fitzgerald"), pursuant to which the Company may offer and sell, from time to time through Cantor Fitzgerald, shares of Common Stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC on March 19, 2018. The Company agreed to pay Cantor Fitzgerald a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During the twelve months ended December 31, 2018 the Company sold 239,270 shares of Common Stock for gross proceeds of $4.31 million and received net proceeds of $4.18 million after deducting sales commissions. On September 27, 2018, the Company also completed a registered public offering with Cantor Fitzgerald as underwriter and sold 811,764 shares its Common stock (including 105,882 shares purchased by Cantor Fitzgerald upon the exercise in full of its right to purchase up to an additional 105,882 shares to cover over-allotments) at a price of $17.00 per share. The Company received approximately $13.0 million of net proceeds from the offering after deducting sales commissions. During the five months ended December 31, 2017 During the five months ended December 31, 2017, the Company issued 145,630 shares of its Common Stock in relation to the cashless exercise of stock options that were granted outside of the Company's 2017 Long-Term Incentive Stock Plan (the "2017 Plan"). These options were for 217,500 shares of Common Stock with exercise prices between $5.00 and $15.00 per share. During the five months ended December 31, 2017, the Company issued 345,000 shares of its Common Stock in relation to the exercise of stock purchase warrants with an exercise price of $15.00 per share for total proceeds of $5,175,000 . During the five months ended December 31, 2017, the Company issued 11,790 shares of its Common Stock in relation to the exercise of stock purchase warrants, with an exercise price of $10.00 per share. The Company received proceeds of $57,900 relating to the warrant exercises during the five months ended December 31, 2017 and the balance of $60,000 on January 16, 2018. On September 23, 2017, the Company issued 3,283 shares of its Common Stock to Torreya. These shares were issued as payment in full for a $100 thousand accrued liability owed by the Company to Torreya pursuant to that certain Supplemental Engagement Letter between the Company and Torreya, dated September 8, 2017 (the "Supplemental Engagement Letter"). The Company valued these shares at $40.58 per share, or approximately $133 thousand in the aggregate, which represents the closing price of the Company's Common Stock on September 22, 2017. The Company recognized a loss on the settlement of the accrued liability of $33 thousand . On December 22, 2017, the Company issued 3,455 shares of its Common Stock to Torreya. These shares were issued as payment in full for a $100 thousand accrued liability owed by the Company to Torreya pursuant to that certain Supplemental Engagement Letter between the Company and Torreya, dated September 8, 2017 (the "Supplemental Engagement Letter"). The Company valued these shares at $24.95 per share, or approximately $81 thousand in the aggregate, which represents the closing price of the Company's Common Stock on December 22, 2017. The Company recognized a gain on the settlement of the liability of $19 thousand . During the year ended July 31, 2017 During the year ended July 31, 2017, the Company issued 2,875 unregistered shares of the Company’s Common Stock to consultants in exchange for services provided by the consultants. The shares issued were valued using the stock price on the issuance date, ranging from $7.52 to $7.75 . The Company recorded a non-cash expense of $22,051 . During the year ended July 31, 2017, the Company issued 25,072 shares of unregistered Common Stock pursuant to the LOI described in Note 10 – Commitments. Under the terms of the LOI, the Company was obligated to issue these shares on the one year anniversary of the LOI and upon the one year anniversary of receipt, by the Company, of a milestone payment from Adapt for the first commercial sale of the Company’s product, NARCAN® , in the U.S. The shares issued in this transaction were valued using the stock price on the issuance dates ranging from $5.94 to $7.75 per share. The Company recorded the aggregate fair value of $168,376 as non-cash expense during the year ended July 31, 2017. The Company made a reconciling adjustment to record the issuance of 6,228 shares of unregistered Common Stock that were issued in fiscal years prior to both 2017 and 2016. Of this total, 6,168 were issued in relation to a conversion of debt into shares of the Company’s common stock. The remaining 60 shares were issued in relation to the Company’s one-for-one hundred reverse stock split of its Common Stock (the “1:100 Reverse Stock Split”) that was effected in December 2014. The 6,228 shares are on a post-split basis and after recording this adjustment the number of shares of the Company’s common stock listed as outstanding on the accompanying Consolidated Statement of Stockholders' Equity (Deficit) reconciles to the actual number of shares outstanding as of July 31, 2017. Stock Options On September 8, 2017, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”), at which time the 2017 Plan was approved by stockholder vote. The 2017 Plan allows the Company to grant both incentive stock options (“ISOs”) and non-qualified stock options (“NSOs”) to purchase a maximum of 400,000 shares of the Company's Common Stock. Under the terms of the 2017 Plan, ISOs may only be granted to Company employees and directors, while NSOs may be granted to employees, directors, advisors, and consultants. The Board has the authority to determine to whom options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value for an ISO or an NSO. The vesting period is normally over a period of four years from the vesting date. The contractual term of an option is no longer than ten years . Prior to adopting the 2017 Plan, the Company did not have a formal long-term incentive stock plan. Prior to the implementation of the 2017 Plan, the Company had discretion to provide designated employees of the Company and its affiliates, certain consultants, and advisors who perform services for the Company and its affiliates, and non-employee members of the Board and its affiliates with the opportunity to receive grants of non-qualified stock options (the "Pre-2017 Non-Qualified Stock Options"). All of the Pre-2017 Non-Qualified Stock Option Grants were intended to qualify as non-qualified stock options. There were no Pre-2017 Non-Qualified Stock Option Grants that were intended to qualify as incentive stock options. No Non-Qualified Stock Options were issued for the year ended December 31, 2018 or the five month transition period ended December 31, 2017. The assumptions used in the valuation for the Pre-2017 Non-Qualified Stock Options for the five months ended December 31, 2017 and for the year ended July 31, 2017 were as follows: December 31, 2017 July 31, 2017 Market value of stock on measurement date $ 36.79 $5.61 to 13.00 Risk-free interest rate 1.47 % 0.88-2.55% Dividend yield 0 % 0 % Volatility factor 96 % 76-348% Term 2.12 years 2.28-10 years Stock option activity for the Pre-2017 Non-Qualified Stock Options for the year ended December 31, 2018 , the five months ended December 31, 2017 and the year ended July 31, 2017 is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at July 31, 2016 4,635,000 8.79 7.39 $ 2,731,250 Granted 320,000 9.38 Expired (5,000 ) 10.00 Forfeited (1,180,000 ) 11.03 Outstanding at July 31, 2017 3,770,000 8.13 6.87 $ 19,139,625 Exercised (217,500 ) 10.22 Forfeited (572,000 ) 11.51 Outstanding at December 31, 2017 2,980,500 7.33 7.06 $ 46,606,210 Exercised (95,000 ) 8.24 Forfeited — — Outstanding at December 31, 2018 2,885,500 7.30 6.04 $ 20,633,100 Exercisable at December 31, 2018 2,747,150 7.20 6.01 $ 19,928,663 A summary of the status of the Company's non-vested Pre-2017 Non-Qualified Stock Options as of December 31, 2018 and changes during the year ended December 31, 2018, the five months ended December 31, 2017 and the year ended July 31, 2017 are presented below: Non-vested options Number of Weighted Average Non-vested at July 31, 2016 90,833 $ 7.27 Granted 320,000 7.70 Vested (70,962 ) 6.70 Non-vested at July 31, 2017 339,871 $ 7.93 Vested (50,969 ) 9.29 Non-vested at December 31, 2017 288,902 $ 7.87 Vested (150,552 ) 7.92 Non-vested at December 31, 2018 138,350 $ 7.84 During the year ended December 31, 2018 the Company recognized approximately $0.9 million of non-cash expense related to vested Pre-2017 Non-Qualified Stock Options granted in prior periods. During the five months ended December 31, 2017, the Company recognized approximately $0.6 million of non-cash expense related to vested Pre-2017 Non-Qualified Stock Options granted in prior periods. During the year ended July 31, 2017 the Company recognized approximately $1.3 million of non-cash expense related to vested Pre-2017 Non-Qualified Stock Options granted in prior periods. At December 31, 2018, there was $0.2 million of unrecognized compensation costs related to non-vested stock options. The 2017 Plan The assumptions used in the valuation of options granted under the 2017 Plan during the year ended December 31, 2018 and the five months ended December 31, 2017 are as follows: Year Ended 12/31/18 Five Months Ended Market value of stock on measurement date $14.31 to $24.84 $18.16 to $49.93 Risk-free interest rate 2.47 % to 3.05% 2.06 % to 2.47% Dividend yield — % — % Volatility factor 121% to 324% 324% to 329% Term (years) 5.5 to 10.0 10.00 Stock option activity for options granted under the 2017 Plan during the year ended December 31, 2018 and the five months ended December 31, 2017 is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at July 31, 2017 — Total options authorized 400,000 Granted (214,000 ) $ 37.62 Expired — Forfeited 40,000 $ 49.93 Outstanding at December 31, 2017 174,000 $ 34.78 9.71 $ 14,430 Exercisable at December 31, 2017 — Annual additional options authorized 101,431 Granted (196,550 ) $ 23.26 Expired — Forfeited 27,000 $ 24.84 Options available at December 31, 2018 157,881 Outstanding at December 31, 2018 343,550 $ 28.97 8.95 $ 840 A summary of the status of the Company’s non-vested options granted under the 2017 Plan as of December 31, 2018 and changes during the year ended December 31, 2018 and the five months ended December 31, 2017 are presented in the following table: Number of Weighted Average Non-vested at July 31, 2017 and 2016 — Granted 214,000 $ 37.62 Forfeited (40,000 ) $ 49.93 Non-vested at December 31, 2017 174,000 $ 34.78 Granted 196,550 $ 23.26 Forfeited (27,000 ) $ 24.84 Non-vested at December 31, 2018 288,047 $ 27.62 Vested at December 31, 2018 55,503 $ 34.66 During the year ended December 31, 2018 and the five months ended December 31, 2017, the Company recognized approximately $4.9 million and $1.2 million of non-cash expense related to vested options granted during these periods. As of December 31, 2018 , there was approximately $3.6 million of unrecognized compensation costs related to non-vested stock options that were granted under the 2017 Plan. Warrants Warrant activity for the year ended December 31, 2018, the five months ended December 31, 2017 and the year ended July 31, 2017 is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at July 31, 2016 1,215,385 $ 17.90 2.86 $ — Granted 45,000 10.00 Expired (166,585 ) $ 46.37 Forfeited (325,000 ) 15 Outstanding at July 31, 2017 768,800 $ 12.50 3.04 $ 1,184,000 Exercised (356,790 ) 14.83 Forfeited (55,000 ) $ 15.00 Outstanding at December 31, 2017 357,010 $ 9.78 5.57 $ 4,708,020 Exercised (3,400 ) $ 10.00 Outstanding at December 31, 2018 353,610 $ 9.78 4.60 $ 1,651,165

Sale of Royalties

Sale of Royalties	12 Months Ended
	Dec. 31, 2018
Sale Of Royalties [Abstract]
Sale of Royalties	Sale of Royalties On December 13, 2016, the Company entered into the SWK Purchase Agreement with SWK pursuant to which the Company sold, and SWK purchased, the Company’s right to receive, commencing on October 1, 2016, all Royalties (as defined in the SWK Purchase Agreement) arising from the sale by Adapt, pursuant to the Adapt Agreement of NARCAN or any other intranasal naloxone opioid overdose reversal treatment, up to (i) $20,625,000 million and then the Residual Royalty thereafter or (ii)$ 26,250,000 , if Adapt has received in excess of $25,000,000 of cumulative Net Sales for any two consecutive fiscal quarters during the period from October 1, 2016 through September 30, 2017 from the sale of NARCAN® (the “Earn Out Milestone”), and then the Residual Royalty thereafter. The Residual Royalty is defined in the Purchase Agreement as follows: (i) if the Earn Out Milestone is paid, then SWK will receive 10% of all Royalties; provided, however, if no generic version of NARCAN® is commercialized prior to the six th anniversary of the Closing, then SWK shall receive 5% of all Royalties after such date, and (ii) if the Earn Out Milestone is not paid, then SWK will receive 7.86% of all Royalties; provided, however, that if no generic version of NARCAN® is commercialized prior to the six th anniversary of the Closing, then SWK will receive 3.93% of all Royalties after such date. Under the Purchase Agreement, the Company received an upfront purchase price of $13,750,000 less $40,000 of legal fees at Closing, and will receive an additional $3,750,000 if the Earn Out Milestone is achieved (the “Purchase Price”). The Purchase Agreement also grants SWK (i) the right to receive the statements produced by Adapt pursuant to Section 5.6 of the Adapt Agreement and (ii) the right, to the extent possible under the Purchase Agreement, to cure any breach of or default under any Product Agreement by the Company. Under the Purchase Agreement, the Company granted SWK a security interest in the Purchased Assets in the event that the transfer contemplated by the Purchase Agreement is held not to be a sale. The Purchase Agreement also contains other representations, warranties, covenants and indemnification obligations that are customary for a transaction of this nature. Absent fraud by the Company, the Company’s indemnification obligations under the Purchase Agreement shall not exceed, individually or in the aggregate, an amount equal to the Purchase Price plus an annual rate of return of 12% (compounded monthly) as of any date of determination, with a total indemnification cap not to exceed 150% of the Purchase Price, less all Royalties received by SWK, without duplication, under the Purchase Agreement prior to and through resolution of the applicable claim. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Purchase Agreement. During the fiscal year ended July 31, 2017, the Company recognized $17.46 million as revenue because (i) the executed agreement constituted persuasive evidence of an arrangement, (ii) the Company had no current or future performance obligations, (iii) the total consideration was fixed and known at the time of its execution and there were no rights of return, (iv) the $13.71 million cash proceeds received in December 2016 were non-refundable, and (v) the $3,750,000 million Earn Out Milestone that was accrued as an account receivable as of July 31, 2017, and subsequently paid to the Company on August 9, 2017, was earned as of July 31, 2017. As of December 31, 2017, the Company determined that the Capped Royalty Amount provided in the SWK Purchase Agreement has been met. After December 31, 2017, SWK's share of the royalty and milestone payments are reduced to 10% of amounts earned from Adapt.

Potomac Amendment

Potomac Amendment	12 Months Ended
	Dec. 31, 2018
Investments, All Other Investments [Abstract]
Potomac Amendment	Potomac Amendment On April 12, 2017 (the “Potomac Effective Date”), the Company and Potomac Construction Limited (“Potomac”) entered into an amendment (the “Potomac Amendment”) to the following investment agreements with Potomac to provide for (in the case of Potomac Agreement No. 1 and Potomac Agreement No. 2 ), or modify (in the case of Potomac Agreement No. 3, Potomac Agreement No. 4 and Potomac Agreement No. 5 (each as defined below)), the Company’s right to buyback the Interest (as defined in each Potomac Amendment) in each Potomac Agreement (as defined below) from Potomac: (i) that certain Investment Agreement, dated as of April 16, 2013, as clarified by that certain letter agreement dated October 15, 2014 (“Potomac Agreement No. 1”); (ii) that certain Investment Agreement, dated as of May 30, 2013, as clarified by that certain letter agreement dated October 15, 2014 (“Potomac Agreement No. 2”); (iii) that certain Investment Agreement, dated as of September 9, 2014, as clarified by that certain letter agreement dated October 15, 2014 (“Potomac Agreement No. 3”); (iv) that certain Investment Agreement, dated as of October 31, 2014, as clarified by that certain letter agreement dated October 31, 2014 (“Potomac Agreement No. 4”); and (v) that certain Investment Agreement, dated as of December 8, 2015 (“Potomac Agreement No. 5”) ((i)–(v) collectively, the “Potomac Agreements” and, each, a “Potomac Agreement”). As of December 31, 2018, the buyback provisions under the Potomac Amendment for the Potomac Agreement No. 1 and Potomac Agreement No. 2 have expired. Pursuant to the Potomac Amendment, from the Potomac Effective Date until September 30, 2019, the five year anniversary of the date of the Investment (as defined in Potomac Agreement No. 3) (the “Potomac Interest No. 3 Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Interest (as defined in Potomac Agreement No. 3) from Potomac upon written notice to Potomac (the “Potomac Interest No. 3 Buyback Notice”), at the price of $500,000 per 0.98% of Interest (the “Potomac Interest No. 3 Buyback Amount”); provided, that in the event the Potomac Interest No. 3 Buyback Notice is provided within 3.25 years of the date of the Investment, the Company shall pay Potomac 1.8 times the Potomac Interest No. 3 Buyback Amount within ten business days of providing the Potomac Interest No. 3 Buyback Notice; provided, further, that in the event the Potomac Interest No. 3 Buyback Notice is provided after 3.25 years of the date of the Investment and on or prior to the Potomac Interest No. 3 Buyback Expiration Date, the Company shall pay Potomac 3.15 times the Potomac Interest No. 3 Buyback Amount within ten business days of providing the Potomac Interest No. 3 Buyback Notice. Pursuant to the Potomac Amendment, from the Potomac Effective Date until November 28, 2019, the five year anniversary of the date of the Investment (as defined in Potomac Agreement No. 4) (the “Potomac Interest No. 4 Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Interest (as defined in Potomac Agreement No. 4) from Potomac upon written notice to Potomac (the “Potomac Interest No. 4 Buyback Notice”), at the price of $500,000 per 0.98% of Interest (the “Potomac Interest No. 4 Buyback Amount”); provided, that in the event the Potomac Interest No. 4 Buyback Notice is provided within 3.25 years of the date of the Investment, the Company shall pay Potomac 1.8 times the Potomac Interest No. 4 Buyback Amount within ten business days of providing the Potomac Interest No. 4 Buyback Notice; provided, further, that in the event the Potomac Interest No. 4 Buyback Notice is provided after 3.25 years of the date of the Investment and on or prior to the Potomac Interest No. 4 Buyback Expiration Date, the Company shall pay Potomac 3.15 times the Potomac Interest No. 4 Buyback Amount within ten business days of providing the Potomac Interest No. 4 Buyback Notice. Pursuant to the Potomac Amendment, from the Potomac Effective Date until December 17, 2020, the five year anniversary of the date of the Investment (as defined in Potomac Agreement No. 5) (the “Potomac Interest No. 5 Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Interest (as defined in Potomac Agreement No. 5) from Potomac upon written notice to Potomac (the “Potomac Interest No. 5 Buyback Notice”), at the price of $500,000 per 0.75% of Interest (the “Potomac Interest No. 5 Buyback Amount”); provided, that in the event the Potomac Interest No. 5 Buyback Notice is provided within 3.25 years of the date of the Investment, the Company shall pay Potomac 1.8 times the Potomac Interest No. 5 Buyback Amount within ten business days of providing the Potomac Interest No. 5 Buyback Notice; provided, further, that in the event the Potomac Interest No. 5 Buyback Notice is provided after 3.25 years of the date of the Investment and on or prior to the Potomac Interest No. 5 Buyback Expiration Date, the Company shall pay Potomac 3.15 times the Potomac Interest No. 5 Buyback Amount within ten business days of providing the Potomac Interest No. 5 Buyback Notice. Pursuant to the Potomac Amendment, if the Additional Investment (as defined in Potomac Agreement No. 5) is funded by Potomac, then, from the date of funding of such Additional Investment until the five year anniversary of such funding date (the “Potomac Additional Interest Buyback Expiration Date”), the Company shall have the right to buyback all or any portion of the Additional Interest (as defined in Potomac Agreement No. 5) upon written notice to Potomac (the “Potomac Additional Interest Buyback Notice”), at the price of $500,000 per 0.75% of Additional Interest (the “Potomac Additional Interest Buyback Amount”); provided, that in the event the Potomac Additional Interest Buyback Notice is provided within 3.25 years of the date of the Additional Investment, the Company shall pay Potomac 1.8 times the Potomac Additional Interest Buyback Amount within ten business days of providing the Potomac Additional Interest Buyback Notice; provided, further, that in the event the Potomac Additional Interest Buyback Notice is provided after 3.25 years of the date of the Additional Investment and on or prior to the Potomac Additional Interest Buyback Expiration Date, the Company shall pay Potomac 3.15 times the Potomac Additional Interest Buyback Amount within ten business days of providing the Potomac Additional Interest Buyback Notice. However, Potomac opted, at its sole discretion, not to make the $1,000,000 Additional Investment, and the deadline for Potomac to make the Additional Investment has passed. In consideration for Potomac entering into the Potomac Amendment, the Company agreed to pay Potomac, within 15 business days of the Potomac Effective Date, $159,500 . The Company recorded the $159,500 payment to Potomac as a non-recurring general and administrative expense during the year ended July 31, 2017. Furthermore, the Company granted Potomac the right to receive 2.5525% of the Net Profit (as defined in the Potomac Agreements) generated from DAVINCI (as defined in the Potomac Amendment). In the event that the Company is sold, Potomac will receive 2.5525% of the net proceeds of such sale, after the deduction of all expenses and costs related to such sale. Additionally, from the Potomac Effective Date until the four year anniversary of the Potomac Effective Date (the “Potomac DAVINCI Interest Buyback Expiration Date”), the Company may buyback all or any portion of the DAVINCI Interest (as defined in the Potomac Amendment) upon written notice to Potomac (the “Potomac DAVINCI Interest Buyback Notice), at the price of $382,875 per 2.5525% of DAVINCI Interest (the “Potomac DAVINCI Interest Buyback Amount”); provided, that in the event the Potomac DAVINCI Interest Buyback Notice is provided within 2.5 years of the Potomac Effective Date, the Company shall pay Potomac two times the Potomac DAVINCI Interest Buyback Amount within ten business days of providing the Potomac DAVINCI Interest Buyback Notice; provided, further, that, in the event the Potomac DAVINCI Interest Buyback Notice is provided after 2.5 years of the Potomac Effective Date and on or prior to the Potomac DAVINCI Interest Buyback Expiration Date, the Company will pay Potomac 3.5 times the Potomac DAVINCI Interest Buyback Amount within ten business days of providing the Potomac DAVINCI Interest Buyback Notice. Furthermore, pursuant to the Potomac Amendment, the Company and Potomac agree that, upon the Company’s receipt after the Potomac Effective Date of at least $3 million from (i) SWK pursuant to the Purchase Agreement with SWK, or (ii) Adapt pursuant to the Adapt Agreement, fifty percent of all actual amounts received by the Company from SWK shall be used in determining the Net Profit.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities using the asset and liability method. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. This method requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2018, the Company’s deferred tax assets relate to net operating loss (“NOL”) carryforwards that were derived from operating losses and stock based compensation from prior years. A full valuation allowance has been applied to the Company’s deferred tax assets. The valuation allowance will be reduced when and if the Company determines it is more likely than not that the related deferred income tax assets will be realized. At December 31, 2018, the Company had federal and state net operating loss carry forwards, which are available to offset future taxable income, of 5,753,943 . The Company’s NOL carryforwards can be carried forward to offset future taxable income for a period of 20 years for each tax year’s loss. These NOL carryforwards begin to expire in 2026. No provision was made for federal income taxes as the Company has significant NOLs. All of the Company's income tax years remained open for examination by taxing authorities. The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate to the net loss before provision for income taxes for the following reasons: December 31, 2018 December 31, 2017 July 31, 2017 Net loss before taxes at statutory rate $ (6,015,352 ) $ 919,111 $ 2,992,311 Permanent items 1,471,275 4,056 5,828 Temporary items 2,444,934 (698,380 ) 385,910 Income tax expense at statutory rate (2,099,143 ) 224,787 3,384,049 Valuation allowance 2,150,426 (55,624 ) (2,833,575 ) Income tax expense per books $ 51,283 $ 169,163 $ 550,474 Net deferred tax assets consist of the following components as of: December 31, 2018 December 31, 2017 July 31, 2017 Net operating loss carryover at statutory rate $ 5,753,943 $ 2,869,510 $ 4,936,604 Stock-based compensation expense 4,939,759 7,404,037 9,922,093 Fixed asset depreciation — (353 ) (2,470 ) Intangibles amortization (1,148 ) (1,012 ) — Other 2,046,961 (290,775 ) — Total $ 12,739,515 $ 9,981,407 $ 14,856,227 Valuation allowance $ (12,739,515 ) $ (9,981,407 ) $ (14,856,227 ) Net deferred tax asset $ — $ — $ — The Company had no uncertain tax positions at December 31, 2018 , December 31, 2017 and July 31, 2017. On December 22, 2017, H.R. 1, formally known as the Tax Cut and Jobs Act (the "Act") was enacted into law. The Act provides for significant tax law changes and modifications with varying effective dates. The major change that affects the Company is reducing the corporate income tax rate from 35% to 21%. In connection with the Company’s initial analysis of the impact of the Tax Act, no discrete net tax benefit or expense in the period ended December 31, 2017 is recorded. This is primarily due to the change in valuation allowance offsets a net benefit or expense for the corporate rate reduction. Open federal tax years are July 31, 2015, July 31, 2016, July 31, 2017, and December 31, 2017. Open state tax years are July 31, 2014, July 31, 2015, July 31, 2016, July 31, 2017 and December 31, 2017.

Comparative Financials (Unaudit

Comparative Financials (Unaudited)	12 Months Ended
	Dec. 31, 2018
Comparative Financial Information Disclosure [Abstract]
Comparative Financials (Unaudited)	Comparative Financials (Unaudited) The Company changed its fiscal year end from July 31 to December 31 effective December 31, 2017. The unaudited consolidated results of operations for the year ended December 31, 2017 is as follows: For the Year Ended (in thousands) December 31, 2017 (unaudited) Revenue: Royalty and licensing revenue $ 15,447 Treatment investment revenue 105 Grant and contract revenue — Total revenue 15,552 Operating expenses: General and administrative 10,313 Research and development 4,857 Royalty expense 1,408 Selling expense 851 Total operating expenses 17,429 Income from operations (1,877 ) Other income, net 68 Income before provision of income taxes (1,809 ) Provision for income taxes 797 Net loss $ (2,606 )

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On January 3, 2019 and January 15, 2019, the Company granted options to employees to purchase in aggregate 76,500 and 13,200 shares of the Company’s Common Stock at an exercise price of $13.61 and $14.62 per share, respectively, which represents the per share closing price of the Company’s Common Stock on the dates of grant. These options were issued under the 2017 Plan and have a ten year term. The options vest as follows: 1/48th of the option shares vest every month on the anniversary of the grant date. From January 1, 2019 through March 15, 2019, the Company issued a total of 80,000 shares of Common Stock in connection with stock option exercises. As a result of the stock option exercises, the Company received aggregate proceeds of $601,250 . On February 21, 2019, the Company announced that its Phase 2 clinical trial evaluating OPNT001, a naloxone nasal spray for the treatment of bulimia nervosa did not meet the primary endpoint of reducing the number of binging days from baseline to week eight. Key secondary endpoints were also not met. Based on these results, the Company will not devote additional resources to the development of OPNT001. On March 18, 2019, the Company and Adapt entered into Amendment No. 2 to the License Agreement. Amendment No. 2 sets forth the timing and amounts that Adapt is allowed to deduct going forward from royalties and milestones payable to the Company and SWK in relation to payments that Adapt has paid or will pay under a license agreement with a Third Party (as defined in the License Agreement), as further discussed in Note 9. Licensee Fee Payable. As provided in Amendment No. 2, going forward Adapt may only deduct a maximum of $9.0 million from royalties and milestones payable to the Company and SWK under the License Agreement in regards to the Third Party license agreement entered into by Adapt on or around February 28, 2018. Under Amendment No. 2, with respect to $6.5 million of the $9 million , Adapt may only deduct a maximum of $2.0 million in any one calendar quarter from the royalties payable to the Company under the License Agreement and SWK under the SWK Purchase Agreement. As provided in the License Agreement, if Net Narcan Sales (as defined in the License Agreement) exceeds $200 million in any calendar year, the Company and SWK will be due a milestone of $15.0 million . Under Amendment No. 2, if this $15.0 million milestone becomes payable to the Company and SWK, Adapt may deduct $2.5 million from this $15.0 million milestone, along with any outstanding balance of the $6.5 million that has not already been deducted in previous quarters. Amendment No. 2 also amended Section 5.5 of the License Agreement to provide that Adapt may still enter into Third Party licensing arrangements; however, in order to exercise its right to deduct any payments with respect thereto, with certain specified exceptions, after March 18, 2019, Adapt will need the consent of the Company that the licensing arrangement is acceptable under the provisions of Amendment No. 2 (in particular the amended Section 5.5 set forth therein). In all instances, any Third Party licensing arrangement and associated deductions taken by Adapt must comply with the provisions of Section 5.5 as amended by Amendment No. 2.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”).
Principles of Consolidation	The consolidated financial statements have been prepared in accordance with GAAP and include the accounts for the Company and its wholly-owned subsidiary, Opiant Pharmaceuticals UK Limited. All inter-company transactions and balances have been eliminated in consolidation.
Use of Estimates	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Accounts Receivable	The Company routinely assesses the recoverability of receivables to determine their collectability by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay. The Company determines its allowance for doubtful accounts by considering such factors as the length of time balances are past due, the Company’s previous loss history, the customer’s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole.
Long-Lived Assets	The Company follows ASC 360, Property, Plant, and Equipment , for its fixed assets. Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed by the straight-line method over estimated useful lives ( 3 to 7 years ). The Company’s capitalizes all asset purchases greater than $2,500 having a useful life greater than one year. The Company follows ASC 350, Intangibles – Goodwill and Other for its intellectual property asset. Intellectual property consists of patents which are stated at their fair value acquisition cost. Amortization is calculated by the straight-line method over their estimated useful lives ( 20 years ). The Company recorded depreciation and amortization of $2,556 for the year ended December 31, 2018, $2,142 for the five months ended December 31, 2017 and $5,140 and for the year ended July 31, 2017. Long-lived assets such as property and equipment and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required, impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets.
Earnings (Loss) per Share	The Company follows ASC 260, Earnings per Share . Basic earnings (loss) per share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the respective period presented in the Company’s accompanying consolidated financial statements. Fully diluted earnings (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of Common Stock equivalents (primarily outstanding options and warrants). Common Stock equivalents represent the dilutive effect of the assumed exercise of outstanding stock options and warrants, using the treasury stock method, at either the beginning of the respective period presented or the date of issuance, whichever is later, and only if the Common Stock equivalents are considered dilutive based upon the Company’s net income position at the calculation date.
Research and Development Costs	The Company follows ASC 730, Research and Development , and expenses all research and development costs as incurred for which there is no alternative future use. These costs also include the expensing of employee compensation and employee stock based compensation
Foreign Currency Translation	The Company’s functional and reporting currency is the United States dollar. Transactions occur in British Pounds and management has adopted ASC 830, Foreign Currency Translation Matters . Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.
Stock-Based Compensation	ASC 718 Compensation – Stock Compensation prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity – Based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.
Fair Value of Financial Instruments	ASC 820 Fair Value Measurements and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1)market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The fair value of the Company’s note payable is estimated based on current rates that would be available for debt of similar terms which is not significantly different from its stated value.
Related Parties	The Company follows ASC 850, Related Party Disclosures , for the identification of related parties and disclosure of related party transactions.
Revenue Recognition, Revenue from Contract with Customer	The Company generates a large majority of revenue from the agreement with Adapt. During the year ended December 31, 2018 and the five months ended December 31, 2017 the Company recognized 95% and 99% , respectively of revenue from its agreement with Adapt. In May 2014, the FASB issued an accounting standard update (‘ASU”), 2014-09, Revenue from Contracts with Customers (Topic 606). This ASU amends the existing accounting standards for revenue recognition and is based on the principle that revenue should be recognized to depict the transfer of goods or services to a customer at an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On January 1, 2018, the Company adopted the new Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers using the modified retrospective method, and the Company determined the new guidance does not change the Company's policy of revenue recognition. The Company's primary source of revenue is through the recognition of royalty and milestone payments from Adapt. Milestone revenue is recognized upon successful accomplishment of certain sales targets set forth in the Adapt Agreement. Royalty revenue is determined based on the agreed upon royalty rate applied to NARCAN sales reported by Adapt.There are no performance obligations by the Company and the Company recognizes revenue according to the royalty report provided by Adapt on quarterly basis. In regards to treatment revenue, the Company received certain investments from investors in return for an interest in its existing treatments. Investors carry an option to exchange investment into shares of the Company. Revenue is deferred until such time that the option expires or milestones are achieved that eliminate the investor’s right to exercise the option. Once the option has expired, the Company determined its performance obligations under the agreement which typically is to perform R&D services related to treatments and recognizes revenue over a period of time which is usually the expected research and development period. The treatment revenue is disaggregated by program treatments. (See Note 8 to the Consolidated Financial Statements - Deferred Revenue).
Revenue Recognition, Deferred Revenue	In regards to treatment revenue, the Company received certain investments from investors in return for an interest in its existing treatments. Investors carry an option to exchange investment into shares of the Company. Revenue is deferred until such time that the option expires or milestones are achieved that eliminate the investor’s right to exercise the option. Once the option has expired, the Company determined its performance obligations under the agreement which typically is to perform R&D services related to treatments and recognizes revenue over a period of time which is usually the expected research and development period. The treatment revenue is disaggregated by program treatments. (See Note 8 to the Consolidated Financial Statements - Deferred Revenue). In June 2018, the FASB issued guidance clarifying the revenue recognition and measurement issues for grants, contracts, and similar arrangements, ASU Topic 958. Government grants and contracts are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period. The Company has evaluated its grant with NIH and contract with BARDA and determined they are non-exchange transactions and fall withing the scope of ASU 958, and revenue should be recognized in accordance with Topic 958 guidance. Accordingly, the Company recognizes revenue from its grant and contract in the period during which the related costs are incurred, provided that the conditions under which the grants and contracts were provided have been met and only perfunctory performance obligations are outstanding. Licensing Agreement Pursuant to the Adapt Agreement, the Company provided a global license to develop and commercialize the Company’s intranasal naloxone opioid overdose reversal treatment, now known as NARCAN®. On December 15, 2014, the Company entered into a License Agreement with Adapt. Pursuant to the License Agreement, we provided a global license to develop and commercialize our intranasal naloxone opioid overdose reversal treatment, now known as NARCAN®. In addition, on the SWK Closing Date, in connection with the SWK Purchase Agreement, as disclosed below, we entered into the Adapt Amendment which amends the terms of the License Agreement relating to the grant of a commercial sublicense outside of the United States and diligence efforts for commercialization of our Opioid Overdose Reversal Treatment Product. Under the terms of the Adapt Amendment, Adapt is required to use commercially reasonable efforts to commercialize the Opioid Overdose Reversal Treatment Product in the United States In the event that Adapt wishes to grant a commercial sublicense to a third party in the European Union or the United Kingdom, we have agreed to negotiate an additional amendment to the License Agreement to include reduced financial terms with respect to the commercial sublicense. With respect to investments in interests in treatments, if an agreement provides an option that allows the investor in the treatment to convert an interest in a treatment into shares of Common Stock of the Company, then revenue is deferred until such time that the option expires or milestones are achieved that eliminate the investor’s right to exercise the option. Upon expiration of the exercise option, the deliverables of the arrangement are reviewed and evaluated under ASC 606. In the event the investor chooses to convert interests into shares of Common Stock, that transaction will be accounted for similar to a sale of shares of Common Stock for cash.
Recently Issued Accounting Pronouncements	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. In June 2018, the FASB issued ASU No. 2018-07, "Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting," ("ASU 2018-07"), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees. ASU 2018-07 is effective for financial statements issued for annual periods beginning after December 15, 2018, and for the interim periods therein. The adoption of ASU 2018-07 is not expected to have a significant impact on the Company’s consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, "Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract" (ASU No. 2018-15). The new standard describes the accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA). Under the new guidance, customers will assess if a CCA includes a software license and if a CCA does include a software license, implementation and set-up costs will be accounted for consistent with existing internal-use software implementation guidance. Implementation costs associated with a CCA that does not include a software license would be expensed to operating expenses. The standard also provides classification guidance on these implementation costs as well as additional quantitative and qualitative disclosures. The standard is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim periods. Entities can choose to adopt the new guidance prospectively or retrospectively. The Company is assessing this standard and currently believes it will not have any material impact on the consolidated financial statements. In 2018, the FASB issued ASU No. 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This new standard permits entities to reclassify to retained earnings the tax effects stranded in accumulated other comprehensive income ("AOCI") as a result of U.S. tax reform. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company has evaluated the impact and timing of the this standard and has concluded it will not impact the consolidated financial statements. In 2017, the FASB issued ASU No. 2017-07, Compensation-Retirement Benefits (Topic 715), Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.The standard requires that an employer report the service cost component in the same line items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside of operating profit. The amendments in this update are effective for public business entities for annual periods beginning after December 15, 2017, including interim periods within those annual periods. The Company adopted this ASU effective January 1, 2018 and has concluded it will not impact the consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, " Leases" (Topic 842) The new standard requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right-of-use ("ROU") model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The standard is effective on January 1, 2019, with early adoption permitted. The Company adopted the new standard on January 1, 2019, and there is no impact from the adoption of this standard as the current office leases are less than 12 months. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash” ("ASU 2016-18”). The update is effective for fiscal years beginning after December 15, 2017, including interim reporting periods within those fiscal years. The purpose of Update No. 2016-18 is to clarify guidance and presentation related to restricted cash in the statement of cash flows. The amendment requires beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include cash and cash equivalents as well as restricted cash and restricted cash equivalents. The Company adopted this ASU effective January 1, 2018 and has concluded it did not have a material impact on its consolidated financial statements. In October 2016, the FASB issued updated guidance related to the recognition of income tax consequences of an intra-entity transfer of an asset other than inventory. This guidance is effective for the first quarter of tax year 2018. The Company has adopted the guidance and determined that there is no impact on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230)” (“ASU 2016-15”), which seeks to reduce the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. For public entities, Update 2016-15 becomes effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this ASU effective January 1, 2018 and has concluded it did not have a material impact on its consolidated financial statements. In March 2016, the FASB issued Accounting Standards Update No. 2016-09, “ Compensation - Stock Compensation (Topic 718) : Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for financial statements issued for fiscal years beginning December 15, 2016, and interim periods within those fiscal years. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. The guidance provided an entity-wide accounting policy election to account for forfeitures as they occur. The Company has elected to record forfeitures as they occur. The Company has evaluated the requirements of the new guidance and has determined that the impact is not material to its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes ("ASU 2017-17") to simplify the presentation of deferred income taxes. ASU 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015-17 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company has adopted the provisions of Update 2016-15 and determined that there is no impact on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, " Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern ." The amendments in this ASU are intended to provide guidance on the responsibility of reporting entity management. Specifically, this ASU provides guidance to management related to evaluating whether there is substantial doubt about the reporting entity’s ability to continue as a going concern and about related financial statement note disclosures. Although the presumption that a reporting entity will continue to operate as a going concern is fundamental to the preparation of financial statements, prior to the issuance of this ASU, there was no guidance in United States generally accepted accounting principles (United States GAAP) related to the concept. Due to the lack of guidance in United States GAAP, practitioners and their clients often faced challenges in determining whether, when, and how a reporting entity should disclose the relevant information in its financial statements. As a result, the FASB issued this guidance to require management evaluation and potential financial statement disclosures. This ASU is effective for financial statements with periods ending after December 15, 2016. The Company adopted the ASU during 2017 and performed going concern evaluations for its 2018 and 2017 year-end financial statements. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table illustrates the dilutive effect of the assumed exercise of the Company’s outstanding stock options and warrants, using the treasury stock method, as of December 31, 2017 and July 31, 2017, respectively: Year Ended Five Months ended Year Ended Numerator: December 31, 2018 December 31, 2017 July 31, 2017 Net Income (loss) $ (21,195,316 ) $ 1,379,379 $ 6,580,613 Denominator: Denominator for basic income (loss) per share - weighted average shares 2,985,335 2,077,663 2,014,540 Effect of dilutive securities: Equity incentive plans — 2,315,475 221,311 Denominator for diluted income (loss) per share 2,985,335 4,393,138 2,235,851 Income (loss) per share - Basic $ (7.10 ) $ 0.66 $ 3.27 Income (loss) per share - Diluted $ (7.10 ) $ 0.31 $ 2.94

Deferred Revenue (Tables)

Deferred Revenue (Tables)	12 Months Ended
	Dec. 31, 2018
Deferred Revenue Disclosure [Abstract]
Schedule of Deferred Revenue Activity	The following is a summary of the Company’s deferred revenue activity for the year ended December 31, 2018, the five months ended December 31, 2017 and the year ended July 31, 2017: (in thousands) NIH Grant BED Other Total Balance as of July 31, 2016 $ — $ 1,000 $ 1,600 $ 2,600 Recognized as revenue — (39 ) — (39 ) Balance as of July 31, 2017 — 961 1,600 2,561 Recognized as revenue — (66 ) — (66 ) Balance as of December 31, 2017 — 895 1,600 2,495 Cash Received NIH 1,000 — — 1,000 Converted to Equity — — (1,600 ) (1,600 ) Recognized as revenue (432 ) (251 ) — (683 ) Balance as of December 31, 2018 $ 568 $ 644 $ — $ 1,212
Deferred Revenue, by Arrangement	urrent and long-term deferred revenue are detailed in the following table: Deferred Revenue (in thousands) NIH Grant BED Other Total Current portion $ 568 $ 644 $ — $ 1,212 Long-term portion — — — — Total $ 568 $ 644 $ — $ 1,212

Royalty Payable (Tables)

Royalty Payable (Tables)	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Schedule of Royalty Payable	The following table sets forth the royalty payable to certain investors as of December 31, 2018 and December 31, 2017: (in thousands) Net Profit % December 31, 2018 December 31, 2017 Potomac 10.2% $ 422 $ 860 LYL 5.0% 206 421 Welmers 1.5% 62 127 Foundation 6.0% 248 — Pendergast 1.0% 60 — Royalty payable 23.7% $ 998 $ 1,408

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
Schedule of Assumptions Used in the Valuation	The assumptions used in the valuation of options granted under the 2017 Plan during the year ended December 31, 2018 and the five months ended December 31, 2017 are as follows: Year Ended 12/31/18 Five Months Ended Market value of stock on measurement date $14.31 to $24.84 $18.16 to $49.93 Risk-free interest rate 2.47 % to 3.05% 2.06 % to 2.47% Dividend yield — % — % Volatility factor 121% to 324% 324% to 329% Term (years) 5.5 to 10.0 10.00 The assumptions used in the valuation for the Pre-2017 Non-Qualified Stock Options for the five months ended December 31, 2017 and for the year ended July 31, 2017 were as follows: December 31, 2017 July 31, 2017 Market value of stock on measurement date $ 36.79 $5.61 to 13.00 Risk-free interest rate 1.47 % 0.88-2.55% Dividend yield 0 % 0 % Volatility factor 96 % 76-348% Term 2.12 years 2.28-10 years
Share-based Compensation, Stock Options, Activity	Stock option activity for the Pre-2017 Non-Qualified Stock Options for the year ended December 31, 2018 , the five months ended December 31, 2017 and the year ended July 31, 2017 is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at July 31, 2016 4,635,000 8.79 7.39 $ 2,731,250 Granted 320,000 9.38 Expired (5,000 ) 10.00 Forfeited (1,180,000 ) 11.03 Outstanding at July 31, 2017 3,770,000 8.13 6.87 $ 19,139,625 Exercised (217,500 ) 10.22 Forfeited (572,000 ) 11.51 Outstanding at December 31, 2017 2,980,500 7.33 7.06 $ 46,606,210 Exercised (95,000 ) 8.24 Forfeited — — Outstanding at December 31, 2018 2,885,500 7.30 6.04 $ 20,633,100 Exercisable at December 31, 2018 2,747,150 7.20 6.01 $ 19,928,663 Stock option activity for options granted under the 2017 Plan during the year ended December 31, 2018 and the five months ended December 31, 2017 is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at July 31, 2017 — Total options authorized 400,000 Granted (214,000 ) $ 37.62 Expired — Forfeited 40,000 $ 49.93 Outstanding at December 31, 2017 174,000 $ 34.78 9.71 $ 14,430 Exercisable at December 31, 2017 — Annual additional options authorized 101,431 Granted (196,550 ) $ 23.26 Expired — Forfeited 27,000 $ 24.84 Options available at December 31, 2018 157,881 Outstanding at December 31, 2018 343,550 $ 28.97 8.95 $ 840
Schedule of Nonvested Share Activity	A summary of the status of the Company’s non-vested options granted under the 2017 Plan as of December 31, 2018 and changes during the year ended December 31, 2018 and the five months ended December 31, 2017 are presented in the following table: Number of Weighted Average Non-vested at July 31, 2017 and 2016 — Granted 214,000 $ 37.62 Forfeited (40,000 ) $ 49.93 Non-vested at December 31, 2017 174,000 $ 34.78 Granted 196,550 $ 23.26 Forfeited (27,000 ) $ 24.84 Non-vested at December 31, 2018 288,047 $ 27.62 Vested at December 31, 2018 55,503 $ 34.66 A summary of the status of the Company's non-vested Pre-2017 Non-Qualified Stock Options as of December 31, 2018 and changes during the year ended December 31, 2018, the five months ended December 31, 2017 and the year ended July 31, 2017 are presented below: Non-vested options Number of Weighted Average Non-vested at July 31, 2016 90,833 $ 7.27 Granted 320,000 7.70 Vested (70,962 ) 6.70 Non-vested at July 31, 2017 339,871 $ 7.93 Vested (50,969 ) 9.29 Non-vested at December 31, 2017 288,902 $ 7.87 Vested (150,552 ) 7.92 Non-vested at December 31, 2018 138,350 $ 7.84
Share-based Compensation, Warrant Activity	Warrant activity for the year ended December 31, 2018, the five months ended December 31, 2017 and the year ended July 31, 2017 is presented in the table below: Number of Weighted- Weighted- Aggregate Outstanding at July 31, 2016 1,215,385 $ 17.90 2.86 $ — Granted 45,000 10.00 Expired (166,585 ) $ 46.37 Forfeited (325,000 ) 15 Outstanding at July 31, 2017 768,800 $ 12.50 3.04 $ 1,184,000 Exercised (356,790 ) 14.83 Forfeited (55,000 ) $ 15.00 Outstanding at December 31, 2017 357,010 $ 9.78 5.57 $ 4,708,020 Exercised (3,400 ) $ 10.00 Outstanding at December 31, 2018 353,610 $ 9.78 4.60 $ 1,651,165

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate to the net loss before provision for income taxes for the following reasons: December 31, 2018 December 31, 2017 July 31, 2017 Net loss before taxes at statutory rate $ (6,015,352 ) $ 919,111 $ 2,992,311 Permanent items 1,471,275 4,056 5,828 Temporary items 2,444,934 (698,380 ) 385,910 Income tax expense at statutory rate (2,099,143 ) 224,787 3,384,049 Valuation allowance 2,150,426 (55,624 ) (2,833,575 ) Income tax expense per books $ 51,283 $ 169,163 $ 550,474
Schedule of Deferred Tax Assets and Liabilities	Net deferred tax assets consist of the following components as of: December 31, 2018 December 31, 2017 July 31, 2017 Net operating loss carryover at statutory rate $ 5,753,943 $ 2,869,510 $ 4,936,604 Stock-based compensation expense 4,939,759 7,404,037 9,922,093 Fixed asset depreciation — (353 ) (2,470 ) Intangibles amortization (1,148 ) (1,012 ) — Other 2,046,961 (290,775 ) — Total $ 12,739,515 $ 9,981,407 $ 14,856,227 Valuation allowance $ (12,739,515 ) $ (9,981,407 ) $ (14,856,227 ) Net deferred tax asset $ — $ — $ —

Comparative Financials (Unaud_2

Comparative Financials (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2018
Comparative Financial Information Disclosure [Abstract]
Condensed Financial Statements	The Company changed its fiscal year end from July 31 to December 31 effective December 31, 2017. The unaudited consolidated results of operations for the year ended December 31, 2017 is as follows: For the Year Ended (in thousands) December 31, 2017 (unaudited) Revenue: Royalty and licensing revenue $ 15,447 Treatment investment revenue 105 Grant and contract revenue — Total revenue 15,552 Operating expenses: General and administrative 10,313 Research and development 4,857 Royalty expense 1,408 Selling expense 851 Total operating expenses 17,429 Income from operations (1,877 ) Other income, net 68 Income before provision of income taxes (1,809 ) Provision for income taxes 797 Net loss $ (2,606 )

Organization and Basis of Pre_2

Organization and Basis of Presentation (Details) - $ / shares	Oct. 02, 2017	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017	Mar. 31, 2017
Business Acquisition [Line Items]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Opiant Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Conversion of stock, shares issued (in shares)	1

Liquidity and Financial Condi_2

Liquidity and Financial Condition (Details) - USD ($)	Sep. 27, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net Income (loss)		$ 1,379,379	$ (21,195,316)	$ (2,606,000)	$ 6,580,613
Accumulated deficit		$ 53,225,350	74,420,666	$ 53,225,350	$ 54,604,729
Working capital			$ 19,500,000
Sale of stock, number of shares issued (in shares)			239,270
Sale of stock, consideration received			$ 4,180,000
Sale of stock, gross proceeds			$ 4,310,000
Public Offering
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sale of stock, number of shares issued (in shares)	811,764
Sale of stock, price per share (in dollars per share)	$ 17
Sale of stock, consideration received	$ 13,000,000
Over-Allotment Option
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sale of stock, number of shares issued (in shares)	105,882

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017	Jul. 31, 2016
Accounting Policies [Abstract]
Cash and cash equivalents	$ 24,613,638	$ 8,115,903	$ 6,872,555	$ 1,481,393

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($)	Jul. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Concentration Risk [Line Items]
Allowance for doubtful accounts	$ 0	$ 0	$ 0
Accounts Receivable | Customer Concentration Risk | SWK Funding LLC
Concentration Risk [Line Items]
Percent of revenue recognized	100.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Long-Lived Assets (Details) - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Property, Plant and Equipment [Line Items]
Capitalized asset purchase price (greater than)		$ 2,500
Finite-lived intangible asset, useful life		20 years
Depreciation and amortization	$ 2,142	$ 2,556	$ 5,140
Impairment of long-lived assets	$ 0	$ 0	$ 0
Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		3 years
Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		7 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Earnings (Loss) Per Share (Details) - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017
Accounting Policies [Abstract]
Potentially dilutive common stock equivalents		3,582,560
Basic:
Net Income (loss)	$ 1,379,379	$ (21,195,316)	$ (2,606,000)	$ 6,580,613
Denominator:
Denominator for basic income (loss) per share - weighted average shares (in shares)	2,077,663	2,985,335		2,014,540
Effect of dilutive securities
Equity incentive plans (in shares)	2,315,475	0		221,311
Denominator for diluted income (loss) per share (in shares)	4,393,138	2,985,335		2,235,851
Income (loss) per share - Basic (in dollars per share)	$ 0.66	$ (7.10)		$ 3.27
Income (loss0 per share - Diluted (in dollars per share)	$ 0.31	$ (7.10)		$ 2.94

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Stock-Based Compensation (Details) - USD ($) $ in Millions	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Accounting Policies [Abstract]
Share-based compensation	$ 1.8	$ 5.7	$ 1.7

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2016
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities, fair value	$ 0	$ 0	$ 0

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Related Parties (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2016
Accounting Policies [Abstract]
Related party balance	$ 0	$ 0	$ 0

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)	Dec. 13, 2016	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017
Revenue Recognition, Milestone Method [Line Items]
Royalty and licensing revenue			$ 11,696,676	$ 13,262,321	$ 15,447,000	$ 18,406,142
SWK Purchase Agreement
Revenue Recognition, Milestone Method [Line Items]
Legal fees	$ 40,000				40,000
Milestone payment receivable under purchase agreement	3,750,000				3,750,000
Proceeds from royalties received		$ 13,710,000			17,460,000	$ 17,460,000
Upfront purchase price received under purchase agreement	$ 13,750,000				$ 13,750,000
Sales Revenue, Net [Member] | Adapt Agreement
Revenue Recognition, Milestone Method [Line Items]
Percent of revenue recognized			99.00%	95.00%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended
	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Oct. 02, 2017	Jul. 31, 2017
Related Party Transaction [Line Items]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Percentage of options and warrants	55.00%
Due to related parties					$ 0
Chairman of the Board
Related Party Transaction [Line Items]
Adjustments to additional paid in capital, other	$ 175,498
Related party transaction, penalty rate	35.00%
Share-based compensation forfeited (in shares)	680,000
Chief Executive Officer
Related Party Transaction [Line Items]
Adjustments to additional paid in capital, other	$ 586,328
Share-based compensation forfeited (in shares)	825,000

Accounts Receivable (Details)

Accounts Receivable (Details) - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2018	Jul. 31, 2017
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 11,696,676		$ 4,489,317	$ 3,750,000
Royalty Revenue from Sales of NARCAN
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable			$ 4,484,433
SWK Purchase Agreement
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percent of milestone payments due	90.00%
Accounts receivable	$ 11,696,676			$ 3,750,000
Revenue recognition, percent recognized	90.00%
Milestone payment		$ 3,750,000
SWK Purchase Agreement | Minimum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Cumulative net sales milestone		$ 25,000,000
SWK Purchase Agreement | SWK Funding LLC
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percent of milestone payments due	10.00%

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Details) - USD ($)	1 Months Ended	5 Months Ended	12 Months Ended
	Aug. 31, 2017	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Long-term Purchase Commitment [Line Items]
Prepaid expenses and other current assets		$ 733,328	$ 267,623	$ 164,887
Prepaid expense			194,000
Payments for prepaid research and development supplies		$ 100,000
Research and Development Arrangement
Long-term Purchase Commitment [Line Items]
Payments to acquire in-process research and development	$ 400,000		74,000
Supplies expense			$ 25,000

Deferred Financing Costs (Detai

Deferred Financing Costs (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred financing costs	$ 0	$ 209,042	$ 0

Deferred Revenue - Narrative (D

Deferred Revenue - Narrative (Details)	Sep. 05, 2018shares	May 28, 2016USD ($)	Dec. 23, 2015USD ($)	Oct. 02, 2015USD ($)	Sep. 22, 2015USD ($)	Jul. 20, 2015USD ($)shares	Sep. 17, 2014USD ($)shares	Dec. 17, 2013USD ($)shares	Sep. 30, 2018shares	Dec. 31, 2017USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)	Jul. 31, 2017USD ($)	Apr. 17, 2018USD ($)
Deferred Revenue Arrangement [Line Items]
Proceeds from funding agreement		$ 266,500	$ 715,500	$ 618,000	$ 1,600,000	$ 250,000	$ 500,000	$ 250,000
Interest in asset		0.35533%	0.954%	0.824%	2.1333%	0.50%	1.00%	0.50%
Number of shares issuable term					60 days	60 days	60 days	60 days
Number of shares issuable (in shares) | shares						25,000	62,500	31,250
Recognized as revenue										$ 66,000		$ 683,000		$ 39,000
Grants receivable															$ 7,400,000
Grant and contract revenue												432,000	$ 0
Deferred revenue, period increase (decrease)												1,000,000
Current portion										378,700		1,212,149	378,700	253,619
Long-term portion										2,115,805		$ 0	2,115,805	2,306,527
Scenario, Forecast
Deferred Revenue Arrangement [Line Items]
Grant and contract revenue											$ 2,600,000
Common Stock
Deferred Revenue Arrangement [Line Items]
Issuance of common stock for cash, net of issuance costs (in shares) | shares												1,051,034
Valour | Common Stock
Deferred Revenue Arrangement [Line Items]
Issuance of common stock for cash, net of issuance costs (in shares) | shares	160,000								160,000
Within 2.5 Years
Deferred Revenue Arrangement [Line Items]
Buyback term on ownership percentage					2 years 6 months
Buyback rate					2
After 2.5 Years
Deferred Revenue Arrangement [Line Items]
Buyback term on ownership percentage					2 years 6 months
Buyback rate					3.5
Research and Development Arrangement December 17, 2013
Deferred Revenue Arrangement [Line Items]
Recognized as revenue										36,000		$ 58,000		$ 39,900
Research and Development Arrangement September 17, 2014
Deferred Revenue Arrangement [Line Items]
Recognized as revenue										$ 29,400		156,863	$ 0
Research and Development Arrangement July 20, 2015
Deferred Revenue Arrangement [Line Items]
Recognized as revenue												$ 35,714

Deferred Revenue - Summary of D

Deferred Revenue - Summary of Deferred Revenue Activity (Details) - USD ($) $ in Thousands	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Movement in Deferred Revenue [Roll Forward]
Balance at beginning of period	$ 2,561	$ 2,495	$ 2,600
Cash Received NIH		1,000
Converted to Equity		(1,600)
Recognized as revenue	(66)	(683)	(39)
Balance at end of period	2,495	1,212	2,561
NIH Grant
Movement in Deferred Revenue [Roll Forward]
Balance at beginning of period	0	0	0
Cash Received NIH		1,000
Converted to Equity		0
Recognized as revenue	0	(432)	0
Balance at end of period	0	568	0
BED
Movement in Deferred Revenue [Roll Forward]
Balance at beginning of period	961	895	1,000
Cash Received NIH		0
Converted to Equity		0
Recognized as revenue	(66)	(251)	(39)
Balance at end of period	895	644	961
Other Opioid Treatments
Movement in Deferred Revenue [Roll Forward]
Balance at beginning of period	1,600	1,600	1,600
Cash Received NIH		0
Converted to Equity		(1,600)
Recognized as revenue	0	0	0
Balance at end of period	$ 1,600	$ 0	$ 1,600

Deferred Revenue - Summary Curr

Deferred Revenue - Summary Current vs. Long Term Deferred Revenue (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017	Jul. 31, 2016
Deferred Revenue Arrangement [Line Items]
Current portion	$ 1,212,149	$ 378,700	$ 253,619
Long-term portion	0	2,115,805	2,306,527
Total	1,212,000	2,495,000	2,561,000	$ 2,600,000
NIH Grant
Deferred Revenue Arrangement [Line Items]
Current portion	568,000
Long-term portion	0
Total	568,000	0	0	0
BED
Deferred Revenue Arrangement [Line Items]
Current portion	644,000
Long-term portion	0
Total	644,000	895,000	961,000	1,000,000
Other Opioid Treatments
Deferred Revenue Arrangement [Line Items]
Current portion	0
Long-term portion	0
Total	$ 0	$ 1,600,000	$ 1,600,000	$ 1,600,000

License Fee Payable (Details)

License Fee Payable (Details) - USD ($)	Mar. 18, 2019	Mar. 01, 2018	Dec. 31, 2018	Feb. 28, 2018	Dec. 31, 2017	Jul. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of counterparty payable offset by guarantor				50.00%
Proceeds from milestone payments		$ 6,100,000
License fee payment		5,600,000
License fees			$ 5,400,000		$ 0	$ 0
License fees			$ 2,700,000		$ 0	$ 0
Adapt
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Reduction in Milestone Payment		$ 6,250,000
Subsequent Event
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License fees payable	$ 8,100,000
License fees	5,400,000
License fees	$ 2,700,000
Subsequent Event | License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalties payable under license agreement	90.00%
Subsequent Event | Adapt | SWK Purchase Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum reduction in quarterly royalty payable payments in next twelve months	$ 6,500,000
Milestone payment to be received if requirements are met	2,700,000
Subsequent Event | Third Party Licensee
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum reduction in quarterly royalty payable payments in next twelve months	$ 9,000,000
Subsequent Event | SWK Funding LLC | SWK Purchase Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percent of royalties payable under license agreement	10.00%
Subsequent Event | EBS
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum reduction in quarterly royalty payable payments in next twelve months	$ 1,800,000
Subsequent Event | EBS | SWK Purchase Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum reduction in quarterly royalty payable payments in next twelve months	2,000,000
Milestone payment to be received if requirements are met	2,500,000
Subsequent Event | Narcan
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Minimum sales requirement for milestone payment	200,000,000
Milestone payment to be received if requirements are met	15,000,000
Subsequent Event | Narcan | License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment to be received if requirements are met	$ 13,500,000

Royalty Payable (Details)

Royalty Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Schedule of Royalties [Line Items]
Net Profit %	23.70%
Royalty payable	$ 998	$ 1,408
Potomac
Schedule of Royalties [Line Items]
Net Profit %	10.20%
Royalty payable	$ 422	860
LYL
Schedule of Royalties [Line Items]
Net Profit %	5.00%
Royalty payable	$ 206	421
Welmers
Schedule of Royalties [Line Items]
Net Profit %	1.50%
Royalty payable	$ 62	127
Foundation
Schedule of Royalties [Line Items]
Net Profit %	6.00%
Royalty payable	$ 248	0
Pendergast
Schedule of Royalties [Line Items]
Net Profit %	1.00%
Royalty payable	$ 60	$ 0

Commitments and Contingencies -

Commitments and Contingencies - 2014 Agreement (Details)	Dec. 22, 2017USD ($)$ / sharesshares	Dec. 21, 2017USD ($)	Sep. 23, 2017USD ($)shares	Sep. 22, 2017USD ($)$ / shares	Sep. 08, 2017USD ($)installmenttrading_days	Apr. 25, 2016	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)	Oct. 22, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jul. 31, 2017USD ($)
Other Commitments [Line Items]
Stock issued during period, value, issued for services											$ 882,232		$ 190,427
Stock issued during the period											16,777,666
2014 Consulting Agreement
Other Commitments [Line Items]
Additional consultant fee payable, percentage of perpetuity in excess of $3 million								3.75%		3.75%		3.75%
Sponsor fees												$ 963,600
2016 Consulting Agreement
Other Commitments [Line Items]
Sponsor fees												687,500
Percentage of gross funding up to $20 million						5.00%
Percentage of gross funding over $20 million						3.50%
Accrued liabilities, current								$ 928,500		$ 928,500		928,500
Advisory Services
Other Commitments [Line Items]
Sponsor fees							$ 100,000			439,000	447,000
Other commitment					$ 300,000
Number of installment payments | installment					3
Installment payment period					16 months
Stock issued during period, value, issued for services	$ 100,000	$ 81,000	$ 100,000	$ 133,000	$ 300,000
Milestone payment					$ 140,600
Milestone payment percentage					3.75%
Milestone payment period					15 days
Milestone payment percentage of total consideration with payment					3.375%
Milestone payment percentage of total consideration with payment and additional provision					3.5625%
Milestone period					6 years
Milestone payment percentage of total consideration without payment					3.45525%
Milestone payment percentage of total consideration without payment and with additional provision					3.60263%
Threshold trading days | trading_days					10
Stock issued during period for services (in shares) | shares	3,455		3,283
Share price of stock issued (in dollars per share) | $ / shares	$ 24.95			$ 40.58
Payments for other commitment fees			$ 240,600					100,000	$ 340,600
Accrued liabilities							$ 151,000	$ 639,000		$ 639,000	$ 151,000	$ 639,000	$ 200,000
Stock newly-issued during the period (in shares) | shares							6,498
Stock issued during the period	$ 81,000		$ 133,000				$ 200,000

Commitments and Contingencies_2

Commitments and Contingencies - Binding LOI (Details) - USD ($)	Apr. 19, 2018	Mar. 31, 2018	Mar. 16, 2017	Nov. 10, 2016	Nov. 19, 2015	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Mar. 29, 2018	Jul. 31, 2016
Other Commitments [Line Items]
Stock issued during the period							$ 16,777,666
Market value of stock on measurement date (in dollars per share)									$ 19.18
Letter of Intent
Other Commitments [Line Items]
Stock newly-issued during the period (in shares)	37,866			14,327	14,327		0
Stock issued during the period			$ 83,300	$ 85,100	$ 120,300	$ 776,000	$ 0	$ 83,300
Additional stock issued during the period, upon milestones (in shares)		37,866	10,745		92,634
Shares issued (in shares)										3,582
Obligatory stock issuance period			1 year
Share price of stock issued (in dollars per share)			$ 7.75
Royalties received, threshold for share issuance		$ 2,000,000
Net product sales milestone one		30,000,000
Net product sales milestone two		40,000,000
Net product sales milestone three		55,000,000
Net product sales milestone four		$ 75,000,000
Common stock, value, to be issued									$ 726,000
Letter of Intent | Research and Development Expense
Other Commitments [Line Items]
Stock issued during the period						726,000
Letter of Intent | Other Expense
Other Commitments [Line Items]
Stock issued during the period						$ 50,000

Commitments and Contingencies_3

Commitments and Contingencies - Heroin Vaccine (Details) - License Royalty Commitment - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2016	Dec. 31, 2018	Dec. 31, 2017
Other Commitments [Line Items]
Percentage of royalty net sales	3.00%
Percentage of royalty sublicensed	4.00%
Payments for minimum annual royalty	$ 10,000
Payments for royalties		$ 60,000
Payments for royalties, execution fee		50,000
Royalty expense, monthly rate		833
Maximum
Other Commitments [Line Items]
Fixed milestone payments			$ 715,700
Minimum
Other Commitments [Line Items]
Payments for royalties		$ 10,000

Commitments and Contingencies_4

Commitments and Contingencies - Sublease Agreement (Details) - USD ($) $ in Thousands	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Standish Management, LLC
Other Commitments [Line Items]
Rent expense	$ 150	$ 321	$ 123

Commitments and Contingencies_5

Commitments and Contingencies - LYL Amendment (Details) - USD ($)	Jun. 01, 2017	May 28, 2016	Dec. 23, 2015	Oct. 02, 2015	Sep. 22, 2015	Jul. 20, 2015	Sep. 17, 2014	Dec. 17, 2013
Other Commitments [Line Items]
Proceeds from funding agreement (at least)		$ 266,500	$ 715,500	$ 618,000	$ 1,600,000	$ 250,000	$ 500,000	$ 250,000
LYL Interest Buyback Agreement
Other Commitments [Line Items]
Proceeds from funding agreement (at least)	$ 3,000,000

Commitments and Contingencies_6

Commitments and Contingencies - License Agreement (Details) $ in Thousands	Jun. 22, 2017USD ($)trading_dayspayment	Dec. 31, 2017USD ($)	Dec. 31, 2018USD ($)	Jul. 31, 2017USD ($)
License Agreement
Other Commitments [Line Items]
Upfront payments | payment	2
Percent of upfront payments which may be paid by issuing common stock	50.00%
Percent of average share price	75.00%
Threshold trading days | trading_days	20
Maximum additional product milestone payments	$ 1,800
Maximum additional commercialization milestone payments	$ 5,000
Termination advance notice period	30 days
Rent expense		$ 150	$ 350	$ 200
Supply Agreement
Other Commitments [Line Items]
Other commitment, period	20 years
Material cure period	60 days

Commitments and Contingencies_7

Commitments and Contingencies - Renaissance Agreement (Details)	12 Months Ended
	Dec. 31, 2018
Research and Development Arrangement
Long-term Purchase Commitment [Line Items]
Termination notice period	45 days

Commitments and Contingencies_8

Commitments and Contingencies - Seperation Agreement (Details)	Sep. 12, 2017USD ($)installmentshares	Sep. 05, 2017	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jul. 31, 2017USD ($)
Other Commitments [Line Items]
Accrued salaries and wages			$ 1,083,644	$ 713,489	$ 1,701,359
Separation Agreement
Other Commitments [Line Items]
Expiration period of resignation revocation		7 days
Payments for accrued obligations	$ 1,130,000
Other commitments, payment period	3 days
Payments for postemployment benefits	$ 1,440,000
Options granted (in shares) | shares	948,000
Maximum period of advisement by former officer	12 months
Payments for other commitments			1,610,000
Accrued salaries and wages			$ 962,000
Separation Agreement | Minimum
Other Commitments [Line Items]
Number of installment payments | installment	1
Separation Agreement | Maximum
Other Commitments [Line Items]
Number of installment payments | installment	2

Stockholder's Equity - Common S

Stockholder's Equity - Common Stock (Details) - USD ($)	Dec. 18, 2018	Sep. 27, 2018	Sep. 05, 2018	Jan. 16, 2018	Dec. 22, 2017	Dec. 21, 2017	Sep. 23, 2017	Sep. 22, 2017	Sep. 08, 2017	Dec. 31, 2018	Sep. 30, 2018	Oct. 31, 2017	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from warrant exercise													$ 5,292,876	$ 34,000	$ 0
Stock issued during period, value, issued for services														$ 882,232	$ 190,427
Sales commission percentage												3.00%
Sale of stock, number of shares issued (in shares)														239,270
Sale of stock, gross proceeds														$ 4,310,000
Sale of stock, consideration received														4,180,000
Stock issued during the period														$ 16,777,666
Stock issued in reverse stock splits (in shares)															60
Prior Period Adjustment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)															6,228
Stock issued, conversion of convertible securities (in shares)															6,168
Letter of Intent
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)															25,072
Share-based compensation															$ 168,376
Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period for services (in shares)															2,875
Stock issued during period, value, issued for services															$ 22,051
Advisory Services
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)										6,498
Stock issued during period for services (in shares)					3,455		3,283
Stock issued during period, value, issued for services					$ 100,000	$ 81,000	$ 100,000	$ 133,000	$ 300,000
Share price of stock issued (in dollars per share)					$ 24.95			$ 40.58
Stock issued during the period					$ 81,000		133,000			$ 200,000
Gain (loss) on settlement of accrued liability					$ 19,000		$ (33,000)
Exercise Price Range, $5.00 to $15.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable (in shares)										95,000			217,500	95,000
Exercise Price, $15.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from warrant exercise													$ 5,175,000	$ 34,000
Exercise Price, $10.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from warrant exercise				$ 60,000									$ 57,900
Public Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock, number of shares issued (in shares)		811,764
Sale of stock, consideration received		$ 13,000,000
Sale of stock, price per share (in dollars per share)		$ 17
Over-Allotment Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock, number of shares issued (in shares)		105,882
Torreya
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Accrued liabilities	$ 100,000
Minimum | Letter of Intent
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price of stock issued (in dollars per share)															$ 5.94
Minimum | Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price of stock issued (in dollars per share)															7.52
Minimum | Exercise Price Range, $5.00 to $15.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of options (in dollars per share)										$ 7.25			$ 5	$ 7.25
Maximum | Letter of Intent
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price of stock issued (in dollars per share)															7.75
Maximum | Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price of stock issued (in dollars per share)															$ 7.75
Maximum | Exercise Price Range, $5.00 to $15.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of options (in dollars per share)										10			$ 15	$ 10
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)														1,051,034
Stock issued during period for services (in shares)	38,166													44,664	27,947
Stock issued during period, value, issued for services	$ 782,000													$ 45	$ 28
Stock issued during the period														$ 1,052
Stock issued, conversion of convertible securities (in shares)															6,228
Stock issued upon the exercise of options (in shares)													145,630	50,497
Common Stock | Exercise Price Range, $5.00 to $15.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)													145,630	50,497
Common Stock | Exercise Price, $15.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)													345,000	3,400
Common Stock | Exercise Price, $10.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)													11,790
Common Stock | Valour
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)			160,000								160,000
Common Stock | Torreya
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock newly-issued during the period (in shares)	6,498
Warrant | Exercise Price, $15.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price of warrant (in dollars per share)										$ 10			$ 15	$ 10
Warrant | Exercise Price, $10.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Price of warrant (in dollars per share)													$ 10

Stockholder's Equity - Stock Op

Stockholder's Equity - Stock Options (Details) - 2017 Plan - Employee Stock Option - shares	12 Months Ended
	Dec. 31, 2018	Sep. 08, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum shares authorized (in shares)		400,000
Award vesting period	4 years
Expiration period	10 years

Stockholder's Equity - Schedule

Stockholder's Equity - Schedule of Pre-2017 Non-Qualified Stock Options Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Jul. 31, 2016	Mar. 29, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)			$ 19.18
Pre-2017 Non-Qualified Stock Options | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)	$ 36.79
Risk-free interest rate	1.47%
Risk-free interest rate, minimum	0.88%	0.71%
Risk-free interest rate, maximum	2.55%	2.05%
Dividend yield	0.00%
Volatility factor	96.00%
Volatility factor, minimum	76.00%	124.00%
Volatility factor, maximum	348.00%	373.00%
Term (years)	2 years 1 month 13 days
Pre-2017 Non-Qualified Stock Options | Employee Stock Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)	$ 5.61	$ 7
Term (years)	2 years 3 months 11 days	3 years
Pre-2017 Non-Qualified Stock Options | Employee Stock Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)	$ 13	$ 10
Term (years)	10 years	10 years

Stockholder's Equity - Schedu_2

Stockholder's Equity - Schedule of Pre-2017 Non-Qualified Stock Options Outstanding (Details) - Pre-2017 Non-Qualified Stock Options - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017	Jul. 31, 2016
Number of Shares
Outstanding at beginning of period (in shares)	3,770,000	2,980,500	4,635,000
Granted (in shares)			320,000
Exercised (in shares)	(217,500)	(95,000)
Expired (in shares)			(5,000)
Forfeited (in shares)	(572,000)	0	(1,180,000)
Outstanding at end of period (in shares)	2,980,500	2,885,500	3,770,000	4,635,000
Exercisable (in shares)		2,747,150
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 8.13	$ 7.33	$ 8.79
Granted (in dollars per share)			9.38
Expired (in dollars per share)			10
Exercised (in dollars per share)	10.22	8.24
Forfeited (in dollars per share)	11.51	0	11.03
Outstanding at end of period (in dollars per share)	$ 7.33	7.30	$ 8.13	$ 8.79
Exercisable (in dollars per share)		$ 7.20
Weighted- average Remaining Contractual Term (years)
Outstanding	7 years 22 days	6 years 15 days	6 years 10 months 13 days	7 years 4 months 21 days
Exercisable		6 years 4 days
Aggregate Intrinsic Value (in Thousands)
Outstanding	$ 46,606,210	$ 20,633,100	$ 19,139,625	$ 2,731,250
Exercisable		$ 19,928,663

Stockholder's Equity - Schedu_3

Stockholder's Equity - Schedule of Pre-2017 Non-Qualified Stock Options Nonvested Share Activity (Details) - Pre-2017 Non-Qualified Stock Options - $ / shares	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Number of Shares
Non-vested, beginning balance (in shares)	339,871	288,902	90,833
Granted (in shares)			320,000
Vested (in shares)	(50,969)	(150,552)	(70,962)
Non-vested, ending balance (in shares)	288,902	138,350	339,871
Weighted Average Grant Date Fair Value Per Share
Non-vested, beginning balance (in dollars per share)	$ 7.93	$ 7.87	$ 7.27
Granted (in dollars per share)			7.70
Vested (in dollars per share)	9.29	7.92	6.70
Non-vested, ending balance (in dollars per share)	$ 7.87	$ 7.84	$ 7.93

Stockholder's Equity - Stock _2

Stockholder's Equity - Stock Options, Additional Information (Details) - USD ($) $ in Millions	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Pre-2017 Non-Qualified Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs		$ 0.2
2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs		3.6
Employee Stock Option | Pre-2017 Non-Qualified Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 0.6	0.9	$ 1.3
Employee Stock Option | 2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 1.2	$ 4.9

Stockholder's Equity - Schedu_4

Stockholder's Equity - Schedule of 2017 Plan Valuation Assumptions (Details) - $ / shares	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Mar. 29, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)			$ 19.18
2017 Plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	2.06%	2.47%
Risk-free interest rate, maximum	2.47%	3.05%
Dividend yield	0.00%	0.00%
Volatility factor, minimum	324.00%	121.00%
Volatility factor, maximum	329.00%	324.00%
Term (years)	10 years
2017 Plan | Employee Stock Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)	$ 18.16	$ 14.31
Term (years)		5 years 6 months
2017 Plan | Employee Stock Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market value of stock on measurement date (in dollars per share)	$ 49.93	$ 24.84
Term (years)		10 years

Stockholder's Equity - Schedu_5

Stockholder's Equity - Schedule of 2017 Plan Options Outstanding (Details) - 2017 Plan - USD ($) $ / shares in Units, $ in Thousands	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017	Sep. 08, 2017
Number of Shares
Outstanding at beginning of period (in shares)	0	174,000	0
Total options authorized (in shares)	400,000
Options granted (in shares)	(214,000)	(196,550)
Expired (in shares)	0	0
Forfeited (in shares)	(40,000)	(27,000)
Options available (in shares)		157,881
Outstanding at end of period (in shares)	174,000	343,550	0
Exercisable (in shares)	0
Weighted- average Exercise Price
Granted (in dollars per share)	$ 37.62	$ 23.26
Forfeited (in dollars per share)	49.93	24.84
Outstanding (in dollars per share)	$ 34.78	$ 28.97
Weighted- average Remaining Contractual Term (years)
Outstanding	9 years 8 months 16 days	8 years 11 months 12 days
Aggregate Intrinsic Value (in Thousands)
Outstanding	$ 14,430	$ 840
Employee Stock Option
Number of Shares
Total options authorized (in shares)				400,000
Aggregate Intrinsic Value (in Thousands)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		101,431

Stockholder's Equity - Schedu_6

Stockholder's Equity - Schedule of 2017 Nonvested Share Activity (Details) - 2017 Plan - $ / shares	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017
Number of Shares
Non-vested, beginning balance (in shares)	0	174,000	0
Options granted (in shares)	214,000	196,550
Forfeited (in shares)	(40,000)	(27,000)
Non-vested, ending balance (in shares)	174,000	288,047	0
Weighted Average Grant Date Fair Value Per Share
Granted (in dollars per share)	$ 37.62	$ 23.26
Forfeited (in dollars per share)	49.93	24.84
Non-vested (in dollars per share)	$ 34.78	$ 27.62
Vested (in shares)		55,503
Vested (in dollars per share)		$ 34.66

Stockholder's Equity - Schedu_7

Stockholder's Equity - Schedule of Warrants Outstanding (Details) - Warrant - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jul. 31, 2017	Jul. 31, 2016
Number of Shares
Outstanding at beginning of period (in shares)	768,800	357,010	1,215,385
Expired (in shares)	(356,790)		(166,585)
Granted (in shares)			45,000
Forfeited (in shares)	(55,000)		(325,000)
Exercised (in dollars per share)		(3,400)
Outstanding at end of period (in shares)	357,010	353,610	768,800	1,215,385
Weighted- average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 12.50	$ 9.78	$ 17.90
Expired (in dollars per share)	14.83		46.37
Granted (in dollars per share)			10
Forfeited (in dollars per share)	15		15
Outstanding at end of period (in dollars per share)	$ 9.78	9.78	$ 12.50	$ 17.90
Exercisable (in dollars per share)		$ 10
Weighted- average Remaining Contractual Term (years)
Outstanding	5 years 6 months 26 days	4 years 7 months 6 days	3 years 15 days	2 years 10 months 10 days
Aggregate Intrinsic Value
Outstanding	$ 4,708,020	$ 1,651,165	$ 1,184,000	$ 0

Sale of Royalties (Details)

Sale of Royalties (Details) - USD ($)	Dec. 31, 2017	Dec. 13, 2016	Dec. 31, 2016	Dec. 31, 2017	Sep. 30, 2017	Jul. 31, 2017	Dec. 31, 2018
Schedule of Royalties [Line Items]
Accounts receivable	$ 11,696,676			$ 11,696,676		$ 3,750,000	$ 4,489,317
SWK Purchase Agreement
Schedule of Royalties [Line Items]
Upfront purchase price received under purchase agreement		$ 13,750,000		13,750,000
Legal fees		40,000		40,000
Milestone payment receivable under purchase agreement		$ 3,750,000		3,750,000
Agreement covenant, rate of return		12.00%
Agreement covenant, maximum indemnification cap		150.00%
Proceeds from royalties received			$ 13,710,000	17,460,000		17,460,000
Accounts receivable	$ 11,696,676			$ 11,696,676		$ 3,750,000
SWK Purchase Agreement | Minimum
Schedule of Royalties [Line Items]
Cumulative net sales milestone					$ 25,000,000
SWK Purchase Agreement | SWK Funding LLC
Schedule of Royalties [Line Items]
Royalty and licensing revenue		$ 26,250,000
Royalty revenue, percent received upon milestone payment	10.00%	10.00%
Milestone period		6 years
Percent received upon milestone payment, without commercialization		5.00%
Percent received without milestone payment		7.86%
Percent received without milestone payment, without commercialization		3.93%
SWK Purchase Agreement | SWK Funding LLC | Maximum
Schedule of Royalties [Line Items]
Royalty and licensing revenue		$ 20,625,000

Potomac Amendment (Details)

Potomac Amendment (Details)	Apr. 12, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jul. 31, 2017USD ($)
Investments, All Other Investments [Line Items]
General and administrative		$ 5,887,135	$ 11,263,804	$ 10,313,000	$ 6,530,533
Potomac Amendment
Investments, All Other Investments [Line Items]
Term of investment agreement	4 years
Price of right to buy back interest	$ 382,875
Percent of interest	2.5525%
Earliest period of notice	2 years 6 months
Payment ratio	2
Period of payment after notice	10 days
Latest period of notice, payment ratio	3.5
Payment period	15 days
General and administrative				$ 159,500	$ 159,500
Counterparty right of net profit percentage	2.5525%
Counterparty right of net proceeds upon divestiture	2.5525%
Minimum payment receivable	$ 3,000,000
Net profit determination, percent of actual amounts received	50.00%
Potomac Amendment Agreement 3
Investments, All Other Investments [Line Items]
Term of investment agreement	5 years
Price of right to buy back interest	$ 500,000
Percent of interest	0.98%
Earliest period of notice	3 years 3 months
Payment ratio	1.8
Period of payment after notice	10 days
Latest period of notice, payment ratio	3.15
Potomac Amendment Agreement 4
Investments, All Other Investments [Line Items]
Term of investment agreement	5 years
Price of right to buy back interest	$ 500,000
Percent of interest	0.98%
Earliest period of notice	3 years 3 months
Payment ratio	1.8
Period of payment after notice	10 days
Potomac Amendment Agreement 5
Investments, All Other Investments [Line Items]
Term of investment agreement	5 years
Price of right to buy back interest	$ 500,000
Percent of interest	0.75%
Earliest period of notice	3 years 3 months
Payment ratio	1.8
Period of payment after notice	10 days
Latest period of notice, payment ratio	3.15
Potomac Amendment Agreement 5, Additional
Investments, All Other Investments [Line Items]
Term of investment agreement	5 years
Price of right to buy back interest	$ 500,000
Percent of interest	0.75%
Earliest period of notice	3 years 3 months
Payment ratio	1.8
Period of payment after notice	10 days
Latest period of notice, payment ratio	3.15
Additional investment option	$ 1,000,000

Income Taxes (Details)

Income Taxes (Details) - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Operating loss carryforwards		$ 5,753,943
Income Tax Reconciliation
Net loss before taxes at statutory rate	$ 919,111	(6,015,352)			$ 2,992,311
Permanent items	4,056	1,471,275			5,828
Temporary items	(698,380)	2,444,934			385,910
Income tax expense at statutory rate	224,787	(2,099,143)			3,384,049
Valuation allowance	(55,624)	2,150,426			(2,833,575)
Income tax expense per books	169,163	51,283	$ 797,000	$ 550,474	550,474
Deferred Tax Assets Components
Net operating loss carryover at statutory rate	2,869,510	5,753,943	2,869,510		4,936,604
Stock-based compensation expense	7,404,037	4,939,759	7,404,037		9,922,093
Fixed asset depreciation	(353)	0	(353)		(2,470)
Intangibles amortization	(1,012)	(1,148)	(1,012)		0
Other		2,046,961
Other	(290,775)		(290,775)		0
Total	9,981,407	12,739,515	9,981,407		14,856,227
Valuation allowance	(9,981,407)	(12,739,515)	(9,981,407)		(14,856,227)
Net deferred tax asset	0	0	0		0
Unrecognized tax benefits	$ 0	$ 0	$ 0		$ 0

Comparative Financials (Unaud_3

Comparative Financials (Unaudited) (Details) - USD ($)	5 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2017	Jul. 31, 2016
Revenue:
Royalty and licensing revenue	$ 11,696,676	$ 13,262,321	$ 15,447,000	$ 18,406,142
Treatment investment revenue	65,641	250,549	105,000	39,854
Grant and contract revenue		432,000	0
Total Revenue	11,762,317	13,982,177	15,552,000	18,445,996
Operating expenses:
General and administrative	5,887,135	11,263,804	10,313,000	6,530,533
Research and development	2,486,514	8,478,817	4,857,000	3,171,599
Royalty expense	1,408,012	1,491,099	1,408,012	0
Selling expense	438,625	213,897	851,000	1,651,099
Total operating expenses	10,220,286	35,172,617	17,429,000	11,353,231
Income (loss) from operations	1,542,031	(21,190,440)	(1,877,000)	7,092,765
Total other income	6,511	46,407	68,000	38,322
Income (loss) before provision for income taxes	1,548,542	(21,144,033)	(1,809,000)	7,131,087
Provision for income taxes	169,163	51,283	797,000	550,474	$ 550,474
Net income (loss)	$ 1,379,379	$ (21,195,316)	$ (2,606,000)	$ 6,580,613

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event - USD ($)	Mar. 18, 2019	Jan. 15, 2019	Jan. 03, 2019	Feb. 22, 2019
Subsequent Event [Line Items]
Options granted (in shares)		13,200	76,500
Exercise of stock options (in shares)				80,000
Proceeds from stock options exercised				$ 601,250
Third Party Licensee
Subsequent Event [Line Items]
Maximum reduction in quarterly royalty payable payments in next twelve months	$ 9,000,000
Adapt | SWK Purchase Agreement
Subsequent Event [Line Items]
Maximum reduction in quarterly royalty payable payments in next twelve months	6,500,000
Milestone payment to be received if requirements are met	2,700,000
EBS
Subsequent Event [Line Items]
Maximum reduction in quarterly royalty payable payments in next twelve months	1,800,000
EBS | SWK Purchase Agreement
Subsequent Event [Line Items]
Maximum reduction in quarterly royalty payable payments in next twelve months	2,000,000
Milestone payment to be received if requirements are met	2,500,000
Narcan
Subsequent Event [Line Items]
Minimum sales requirement for milestone payment	200,000,000
Milestone payment to be received if requirements are met	$ 15,000,000
Employee Stock Option
Subsequent Event [Line Items]
Expiration period			10 years
Employee Stock Option | End of one year
Subsequent Event [Line Items]
Granted (in dollars per share)		$ 14.62	$ 13.61
Employee Stock Option | Monthly after year one
Subsequent Event [Line Items]
Award vesting rights, percentage			2.0833%